برجاء الإنتظار ...

Search Results



نشرة الممارس الصحي نشرة معلومات المريض بالعربية نشرة معلومات المريض بالانجليزية صور الدواء بيانات الدواء
  SFDA PIL (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)

Arbavasc HCT tablets contain three substances called amlodipine, valsartan and hydrochlorothiazide. All of these substances help to control high blood pressure.

Amlodipine belongs to a group of substances called "calcium channel blockers". Amlodipine stops calcium from moving into the blood vessel wall, which stops the blood vessels from tightening. Valsartan belongs to a group of substances called "angiotensin-II receptor antagonists". Angiotensin II is produced by the body and makes the blood vessels tighten, thus increasing the blood pressure. Valsartan works by blocking the effect of angiotensin II. Hydrochlorothiazide belongs to a group of substances called "thiazide diuretics". Hydrochlorothiazide increases urine output, which also lowers blood pressure.

As a result of all three mechanisms, the blood vessels relax and blood pressure is lowered.

Arbavasc HCT is used to treat high blood pressure in adult patients whose blood pressure is already controlled while taking amlodipine, valsartan and hydrochlorothiazide and who may benefit from taking one tablet containing all three substances.


Do not take Arbavasc HCT

- If you are more than 3 months pregnant. (It is also recommended to avoid Arbavasc HCT in early pregnancy - see Pregnancy section.)

- If you are allergic to amlodipine or to any other calcium channel blockers, valsartan, hydrochlorothiazide, sulphonamide-derived medicines (medicines used to treat chest or urinary infections), or any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, do not take Arbavasc HCT and talk to your doctor.

- If you have liver disease, destruction of the small bile ducts within the liver (biliary cirrhosis) leading to the buildup of bile in the liver (cholestasis).

- If you have severe kidney problems or if you are having dialysis.

- If you are unable to produce urine (anuria).

- If the level of potassium or sodium in your blood is too low despite treatment to increase the potassium or sodium levels in your blood.

- If the level of calcium in your blood is too high despite treatment to reduce the calcium levels in your blood.

- If you have gout (uric acid crystals in the joints).

- If you have severe low blood pressure (hypotension).

- If you have narrowing of the aortic valve (aortic stenosis) or cardiogenic shock (a condition where your heart is unable to supply enough blood to the body).

- If you suffer from heart failure after a heart attack.

if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren

- If any of the above applies to you, do not take Arbavasc HCT and talk to your doctor.

Warning and precautions

Talk to your doctor or pharmacist before taking Arbavasc HCT

- If you have a low level of potassium or magnesium in your blood (with or without symptoms such as muscle weakness, muscle spasms, abnormal heart rhythm).

- If you have a low level of sodium in your blood (with or without symptoms such as tiredness, confusion, muscle twitching, convulsions).

- If you have a high level of calcium in your blood (with or without symptoms such as nausea, vomiting, constipation, stomach pain, frequent urination, thirst, muscle weakness and twitching).

- If you have kidney problems, have had a kidney transplant or if you had been told that you have a narrowing of your kidney arteries.

- If you have liver problems.

- If you have or have had heart failure or coronary artery disease.

- If you have experienced a heart attack. Follow your doctor's instructions for the starting dose carefully. Your doctor may also check your kidney function.

- If your doctor has told you that you have a narrowing of the valves in your heart (called "aortic or mitral stenosis") or that the thickness of your heart muscle is abnormally increased (called "obstructive hypertrophic cardiomyopathy").

- If you suffer from aldosteronism. This is a disease in which the adrenal glands make too much of the hormone aldosterone If this applies to you, the use of Arbavasc HCT is not recommended.

- If you suffer from a disease called systemic lupus erythematosus (also called "lupus" or "SLE").

- If you have diabetes (high level of sugar in your blood).

- If you have high levels of cholesterol or triglycerides in your blood.

- If you experience skin reactions such as rash after sun exposure.

- If you had an allergic reaction to other high blood pressure medicines or diuretics (a type of medicine also known as "water tablets"), especially if you suffer from asthma and allergies - if you have been sick (vomiting or diarrhoea).

- If you have experienced swelling, particularly of the face and throat, while taking other medicines (including angiotensin converting enzyme inhibitors). If you get these symptoms, stop taking Arbavasc HCT and contact your doctor straight away. You should never take Arbavasc HCT again.

- If you experience dizziness and/or fainting during treatment with Arbavasc HCT, tell your doctor as soon as possible.

-If you experience a decrease in vision or eye pain. These could be symptoms of fluid accumulation
in the vascular layer of the eye (choroidal effusion) or an increase of pressure in your eye and can
happen within hours to weeks6 of taking Arbavasc HCT.
- If you suffer from buildup of fluid between the choroid (the blood vessel layer that nourishes the
overlying retina) and the sclera, the white outer covering of the eye.

- If you are taking any of the following medicines used to treat high blood pressure: - an ACE inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems. - aliskiren. Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals. See also information under the heading "Do not take Arbavasc HCT".

If any of these apply to you, talk to your doctor.

Children and adolescents

The use of Arbavasc HCT in children and adolescents under 18 years of age is not recommended.

Elderly people (age 65 years and older)

Arbavasc HCT can be used by people aged 65 years and over at the same dose as for other adults and in the same way as they have already taken the three substances called amlodipine, valsartan and hydrochlorothiazide. Elderly patients, should have their blood pressure checked regularly.

Other medicines and Arbavasc HCT

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Your doctor may need to change your dose and/or to take other precautions. In some cases, you may have to stop using one of the medicines. This is especially important if you are using any of the medicines listed below:

Do not take together with:

•    lithium (a medicine used to treat some types of depression);

•    medicines or substances that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium sparing medicines and heparin;

•     ACE inhibitors or aliskiren (see also information under the headings "Do not take Arbavasc HCT" and "Warnings and precautions").

Caution should be used with:

•    alcohol, sleeping pills and anaesthetics (medicines allowing patients to undergo surgery and other procedures);

•    amantadine (anti-Parkinson therapy, also used to treat or prevent certain illnesses caused by viruses); • anticholinergic agents (medicines used to treat a variety of disorders such as gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness, muscular spasms, Parkinson's disease and as an aid to anaesthesia);

•    anticonvulsant medicines and mood-stabilising medicines used to treat epilepsy and bipolar disorder (e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone);

•    cholestyramine, colestipol or other resins (substances used mainly to treat high levels of lipids in the blood); • simvastatin (a medicine used to control high cholesterol levels);

•     ciclosporin (a medicine used in transplantation to prevent organ rejection or for other conditions, e.g: rheumatoid arthritis or atopic dermatitis);

•    cytotoxic medicines (used to treat cancer), such as methotrexate or cyclophosphamide;

•     digoxin or other digitalis glycosides (medicines used to treat heart problems);

•    verapamil, diltiazem (heart medicines);

•    iodine contrast media (agents used for imaging examinations);

•     medicines for the treatment of diabetes (oral agents such as metformin or insulins);

•    medicines for the treatment of gout, such as allopurinol;

•     medicines that may increase blood sugar levels (beta blockers, diazoxide);

•    medicines that may induce "torsades de pointes" (irregular heart beat), such as antiarrhythmics (medicines used to treat heart problems) and some antipsychotics;

•    medicines that may reduce the amount of sodium in your blood, such as antidepressants, antipsychotics, antiepileptics;

•     medicines that may reduce the amount of potassium in your blood, such as diuretics (water tablets), corticosteroids, laxatives, amphotericin or penicillin G;

•     medicines to increase blood pressure such as adrenaline or noradrenaline;

•    medicines used for HIV/AIDS (e.g. ritonavir, indinavir, nelfinavir);

•     medicines used to treat fungal infections (e.g. ketoconazole, itraconazole);

•     medicines used for oesophageal ulceration and inflammation (carbenoxolone);

•     medicines used to relieve pain or inflammation, especially non-steroidal anti-inflammatory agents (NSAIDs), including selective cyclooxygenase2- inhibitors (Cox2- inhibitors);

•    muscle relaxants (medicines to relax the muscles which are used during operations);

•     nitroglycerin and other nitrates, or other substances called "vasodilators";

•      other medicines to treat high blood pressure, including methyldopa;

•    rifampicin (used, for example, to treat tuberculosis);

•    St. John's wort;

•    dantrolene (infusion for severe body temperature abnormalities);

•    vitamin D and calcium salts.

Arbavasc HCT with food, drink and alcohol

Grapefruit and grapefruit juice should not be consumed by people who are prescribed Arbavasc HCT. This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active substance amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Arbavasc HCT. Talk to your doctor before drinking alcohol. Alcohol may make your blood pressure fall too much and/or increase the possibility of dizziness or fainting.

Pregnancy and breast-feeding

Pregnancy

You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Arbavasc HCT before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Arbavasc HCT. Arbavasc HCT is not recommended in early pregnancy and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy. Breast-feeding Tell your doctor if you are breast-feeding or about to start breast-feeding. Arbavasc HCT is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is a newborn, or was born prematurely. Ask your doctor or pharmacist for advice before taking any medicine.

Breast-feeding

Tell your doctor if you are breast-feeding or about to start breast-feeding. Arbavasc HCT is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is a newborn, or was born prematurely.

Ask your doctor or pharmacist for advice before taking any medicine.

Driving and using machines

This medicine may make you feel dizzy, drowsy, nauseous or have a headache. If you experience these symptoms, do not drive or use tools or machines.


Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. This will help you get the best results and lower the risk of side effects.

The usual dose of Arbavasc HCT is one tablet per day

It is best to take the tablet at the same time each day. Morning is the best time.

Swallow the tablet whole with a glass of water.

You can take Arbavasc HCT with or without food. Do not take Arbavasc HCT with grapefruit or grapefruit juice.

Depending on how you respond to the treatment, your doctor may suggest a higher or lower dose.

Do not exceed the prescribed dose.

If you take more Arbavasc HCT than you should

If you have accidentally taken too many Arbavasc HCT tablets, talk to a doctor immediately. You may require medical attention.

If you forget to take Arbavasc HCT

If you forget to take a dose of this medicine, take it as soon as you remember and then take the next dose at its usual time. If it is almost time for your next dose you should simply take the next tablet at the usual time. Do not take a double dose (two tablets at once) to make up for a forgotten tablet.

If you stop taking Arbavasc HCT

Stopping your treatment with Arbavasc HCT may cause your disease to get worse. Do not stop taking your medicine unless your doctor tells you to.

Always take this medicine, even if you are feeling well. People who have high blood pressure often do not notice any signs of the problem. Many feel normal. It is very important that you take this medicine exactly as your doctor tells you to get the best results and reduce the risk of side effects. Keep your appointments with the doctor even if you are feeling well.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.


Like all medicines, this medicine can cause side effects, although not everybody gets them.

As for any combination containing three active substances, side effects associated with each individual component cannot be excluded. The side effects reported with Arbavasc HCT or one of its three active substances (amlodipine, valsartan and hydrochlorothiazide) are listed below and may occur with the use of Arbavasc HCT. Some side effects can be serious and need immediate medical attention.

Consult a doctor immediately if you experience any of the following serious side effects after taking this medicine:

Common (may affect up to 1 in 10 people):

•    dizziness

•    low blood pressure (feeling of faintness, lightheadedness, sudden loss of consciousness)

Uncommon (may affect up to 1 in 100 people):

•    severely decreased urine output (decreased kidney function)

Rare (may affect up to 1 in 1,000 people):

•    spontaneous bleeding

•    irregular heart beat

•    liver disorder

Very rare (may affect up to 1 in 10,000 people):

•    sudden wheeziness, chest pain, shortness of breath or difficulty breathing

•    swelling of eyelids, face or lips

•    swelling of the tongue and throat which causes great difficulty breathing

•severe skin reactions including intense skin rash, hives, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, inflammation of the mucous membranes (Stevens-Johnson syndrome) or other allergic reactions

•    heart attack

•    inflamed pancreas, which may cause severe abdominal and back pain accompanied with feeling of being very unwell

•    weakness, bruising, fever and frequent infections

•    stiffness

Other side effects may include:

Very common (may affect more than 1 in 10 people):

•    low level of potassium in the blood

•    increase of lipids in the blood

Common (may affect up to 1 in 10 people):

•    sleepiness

•    palpitations (awareness of your heart beat)

•    flushing

•    ankle swelling (oedema)

•    abdominal pain

•    stomach discomfort after meal

•    tiredness

•    headache

•    frequent urination

•    high level of uric acid in the blood

•    low level of magnesium in the blood

•    low level of sodium in the blood

•    dizziness, fainting on standing up

•    reduced appetite

•    nausea and vomiting

•    itchy rash and other types of rash

•    inability to achieve or maintain erection

Uncommon (may affect up to 1 in 100 people):

•    fast heart beat

•    spinning sensation

•    vision disorder

•    stomach discomfort

•    chest pain

•    increase of urea nitrogen, creatinine and uric acid in the blood

•    high level of calcium, fat or sodium in the blood

•    decrease of potassium in the blood

•    breath odour

•    diarrhoea

•    dry mouth

•    weight increase

•    loss of appetite

•    disturbed sense of taste

•    back pain

•    joint swelling

•    muscle cramps/weakness/pain

•    pain in extremity

•    inability to either stand or walk in a normal manner

•    weakness

•    abnormal coordination

•    dizziness on standing up or after exercising

•    lack of energy

•    sleep disturbances

•    tingling or numbness

•    neuropathy

•    sudden, temporary loss of consciousness

•    low blood pressure on standing up

•    cough

•    breathlessness

•    throat irritation

•    excessive sweating

•    itching

•    swelling, reddening and pain along a vein

•    skin reddening

•    trembling

•    mood changes

•    anxiety

•    depression

•    sleeplessness

•    taste abnormalities

•    fainting

•    loss of pain sensation

•    visual disturbances

•    visual impairment

•    ringing in the ears

•    sneezing/runny nose caused by inflammation of the lining of the nose (rhinitis)

•    altered bowel habits

•    indigestion

•    hair loss

•    itchy skin

•    skin discolouration

•    disorder in passing urine

•    increased need to urinate at night

•    increased number of times of passing urine

•    discomfort or enlargement of the breasts in men

•    pain

•    feeling unwell

•    weight decrease

Rare (may affect up to 1 in 1,000 people):

•    low level of blood platelets (sometimes with bleeding or bruising underneath the skin)

•    sugar in the urine

•    high level of sugar in the blood

•    worsening of the diabetic metabolic state

•    abdominal discomfort

•    constipation

•    liver disorders which can occur together with yellow skin and eyes, or dark-coloured urine (haemolytic anaemia)

•    increased sensitivity of skin to sun

•    purple skin patches

•    kidney disorders

•    confusion

Very rare (may affect up to 1 in 10,000 people):

•    decreased number of white blood cells

•    decrease in blood platelets which may result in unusual brusing or easy bleeding (red blood cell damage)

•    swelling of the gums

•    abdominal bloating (gastritis)

•    inflammation of the liver (hepatitis)

•    yellowing of the skin (jaundice)

•    liver enzyme increase which may have an effect on some medical tests

•    increased muscle tension

•    inflammation of blood vessels often with skin rash

•    sensitivity to light

•    disorders combining rigidity, tremor and/or movement disorders

•    fever, sore throat or mouth ulcers, more frequent infections (lack or low level of white blood cells)

•    pale skin, tiredness, breathlessness, dark coloured urine (haemolytic anaemia, abnormal breakdown of red blood cells either in the blood vessels or elsewhere in the body)

•    confusion, tiredness, muscle twitching and spasm, rapid breathing (hypochloraemic alkalosis)

•    severe upper stomach ache (inflammation of the pancreas)

•    difficulty breathing with fever, coughing, wheezing, breathlessness (respiratory distress, pulmonary oedema, pneumonitis)

•    facial rash, joint pain, muscle disorder, fever (lupus erythematosus)

•    inflammation of blood vessels with symptoms such as rash, purplish-red spots, fever (vasculitis)

•    severe skin disease that causes rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (toxic epidermal necrolysis)

Not known (frequency cannot be estimated from the available data):

•    changes in blood tests for kidney function, increase of potassium in your blood, low level of red blood cells

•    abnormal red blood cell test

•    low level of a certain type of white blood cell and blood platelet

•    increase of creatinine in the blood

•    abnormal liver function test

•    severely decreased urine output

•    inflammation of blood vessels

•    weakness, bruising and frequent infections (aplastic anaemia)

• Decrease in vision or pain in your eyes due to high pressure (possible signs of fluid accumulation
in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma

•    breathlessness

•    severely decreased urine output (possible signs of renal disorder or renal failure)

•    severe skin disease that causes rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (erythema multiforme)

•    muscle spasm

•    fever (pyrexia)

•    blistering skin (sign of a condition called dermatitis bullous)

• Skin and lip cancer (Non-melanoma skin cancer).
• Choroidal effusion (an abnormal accumula�on of fluid in the suprachoroidal space)
 


Keep out of reach and sight of children.

Store below 30 °C.

Do not use Arbavasc HCT after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.


Tha active ingredients are:

Arbavasc HCT (160/5/12.5) contains Valsartan 160mg, Amlodipine 5mg (as Besylate) and Hydrochlorothiazide 12.5 mg

Arbavasc HCT (160/5/25) contains Valsartan 160mg, Amlodipine 5mg and Hydrochlorothiazide 25 mg

Arbavasc HCT (160/10/12.5) contains Valsartan 160mg, Amlodipine 10mg and Hydrochlorothiazide 12.5 mg

Arbavasc HCT (160/10/25) contains Valsartan 160mg, Amlodipine 10mg and Hydrochlorothiazide 25 mg

The other ingredients are: Microcrystalline cellulose, Crospovidone, Colloidal Silicon Dioxide, Magnesium Stearate, Opadry


Arbavasc HCT 160/5/12.5 mg is White Oval shaped biconvex core tablet embossed with SJ523 from one side Arbavasc HCT 160/5/25 mg is Yellow Oval shaped biconvex core tablet embossed with SJ527 from one side Arbavasc HCT 160/10/12.5 mg is Pale yellow oval shaped biconvex film coated tablet embossed with SJ525 in one side Arbavasc HCT 160/10/25 mg is Brownish yellow oval shaped biconvex film coated tablet embossed with SJ531 in one side Each carton contain 28 FC Tablet (4 blisters, each blister contain 7 tablets).

SAJA Pharmaceuticals

Saudi Arabian Japanese pharmaceutical company limited Jeddah - Saudi Arabia

 

To report any side effect(s):
• Saudi Arabia

- The National Pharmacovigilance Centre (NPC):
- SFDA Call Center: 19999
- E-mail: npc.drug@sfda.gov.sa
- Website: https://ade.sfda.gov.sa/
• Other GCC States:
- Please contact the relevant competent authority.
 


April/2022
  نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)

يحتوي عقار أربافاسك إتش سي تي أقراص على ثلاث مواد تُسمى أملوديبين وفالسارتان وهيدروكلوروثيازيد.

تُساعد كل هذه المواد على التحكُّم في ضغط الدم المرتفع.

ينتمي أملوديبين إلى مجموعة من المواد تُسمى: "حاصرات قنوات الكالسيوم". يوقف أملوديبين الكالسيوم عن التَّحرك إلى داخل جدار الأوعية الدَّموية، الأمر الذي يوقف الأوعية الدَّموية عن التَّضيّق وبالتَّالي يُخفِّض أيضًا ضغط الدَّم.

ينتمي فالسارتان إلى مجموعة من المواد تُسمى: "مناهضات مستقبلات الأنجيوتنسين 2". ينتج الجسم هرمون الأنجيوتنسين -2 ويُسبب تضيُّق الأوعية الدَّموية، وبالتَّالي زيادة ضغط الدَّم لديك. يعمَل فالسارتان عن طريق حصر تأثير أنجيوتنسين -٢.

ينتمي هيدروكلوروثيازيد، إلى مجموعة من المواد تُسمى: "مدرات البول الثيازيدية". يُزيد هيدروكلوروثيازيد إخراج البول، مما يُخفِّض أيضًا ضغط الدَّم.

نتيجة لذلك، ترتخي الأوعية الدَّموية، فيقل ضغط الدَّم لديك.

يُستَخدَم عقار أربافاسك إتش سي تي لعلاج ارتفاع ضغط الدَّم في المرضى من البالغين الذين يتم التَّحكُّم بالفعل في ضغط الدَّم لديهم أثناء تناوُل أملوديبين وفالسارتان وهيدروكلوروثيازيد والذين قد يستفيدون من تناوُل قرص واحد يحتوي على الثلاث مواد جميعهم.

لا تتناول عقار أربافاسك إتش سي تي في الحالات الآتية:

- إذا كنتِ حاملاً لأكثر من ٣ أشهر. (من الأفضل أيضًا تجنُّب تناوُل عقار أربافاسك إتش سي تي في مراحل الحمل المبكرة - انظري قسم: "الحمل").

- إذا كنت تُعاني من فرط الحساسية تجاه أملوديبين، أي من حاصرات قنوات الكالسيوم، فالسارتان، هيدروكلوروثيازيد، أي من الأدوية المشتقة من السالفونيميدات (أدوية لعلاج عدوى الصدر أو المسالك البولية) أو أيٍّ من المكونات الأخرى بهذا الدَّواء (المُدرجة في قسم ٦). إذا كنت تعتقد أنَّ لديك حساسية، فتحدَّث إلى طبيبك قبل تناوُل عقار أربافاسك إتش سي تي.

- إذا كنت تُعاني من مرض شديد بالكبد، فقد يحدث تدمير للقنوات الصفراوية الصغيرة داخل الكبد (تليف الكبد الصفراوي) مما يُؤدي إلى تراكم العصارة الصفراوية في الكبد (ركود صفراوي).

- إذا كان لديك مشاكل شديدة في الكلى أو تقوم بغسيل الكلى.

- إذا كنت غير قادر على إخراج البول (انقطاع البول).

- إذا كان مستوى البوتاسيوم أو الصوديوم في دمك منخفضًا للغاية على الرغم من تلقي العلاج فعليك
زيادة مستويات البوتاسيوم أو الصوديوم في دمك.

- إذا كان مستوى الكالسيوم في دمك مرتفعًا للغاية على الرغم من تلقي العلاج فعليك خفض مستويات
الكالسيوم في دمك.

- إذا كنت مُصابًا بمرض النّقرس (بلورات حمض اليوريك في المفاصل).

- إذا كنت تعاني من انخفاض ضغط الدَّم (هبوط).

- إذا كان لديك تضيُّق في الصمام الأورطي أو صدمة قلبية المنشأ (حالة يكون فيها القلب غير قادر على إمداد الجسم بكمية كافية من الدم.

- إذا كنت تعاني من هبوط (فشل) القلب.

- إذا كنت مصابًا بمرض السُّكَّري أو تُعاني من قصور في وظائف الكُلى، ويتم علاجك بدواء خافض لضغط
الدَّم يحتوي على أليسكيرين.

إذا انطبق عليك أي مما سبق، فلا تتناول عقار أربافاسك إتش سي تي وتحدَّث إلى طبيبك.

تحذيرات واحتياطات

تحدَّث إلى الطبيب أو الصيدلي الخاص بك قبل تناول عقار أربافاسك إتش سي تي.

- إذا كان لديك انخفاض في مستوى البوتاسيوم أو الماغنسيوم في دمك (مع أو بدون أعراض مثل ضعف
العضلات، تقلصات عضلية، اضطراب النظْم القلبي).

- إذا كان لديك مستوى منخفض من الصوديوم في دمك (مع أو بدون أعراض مثل: التَّعب، الارتباك، الانتفاض العضلي، التشنُّجات).

- إذا كان لديك مستوى مرتفع من الكالسيوم في دمك (مع أو بدون أعراض مثل: الغثيان والقيء والإمساك
وألم المعدة والتبوُّل المتكرر والعطش وضعف العضلات والانتفاض العضلي).

- إذا كان لديك مشاكل بالكُلى أو خضعت لعملية زرع كُلى أو إذا تم إخبارك أنه لديك تضيُّق في شرايين الكُلى.

- إذا كنت تعاني من مشاكل بالكبد.

- إذا كنت مصابًا أو قد أُصِبت من قبل بفشل القلب أو مرض بالشريان التَّاجي.

- إذا تعرَّضت لنوبة قلبية. اتبع تعليمات طبيبك الخاصة بجرعة البدء بعناية. قد يفحص طبيبك أيضًا وظائف الكُلى لديك.

- إذا أخبرك طبيبك أن لديك تضيُّقًا في صمام القلب (يُسمى "تضيُّق الشريان الأورطي أو الميترالي") أو زيادة سمك عضلة القلب بشكل غير طبيعي (يُسمى: "اعتلال عضلة القلب التضخمي الانسدادي").

- إذا كنت تعاني من فرط الألدوستيرونية. يُعَد هذا مرضًا تقوم فيه الغدة الكظرية بصُنع كمية كبيرة جدًّا من هرمون الألدوستيرون. إذا انطبق ذلك عليك، لا يوصى باستخدام عقار أربافاسك إتش سي تي.

- إذا كنت تُعاني من مرض يُسمى الذئبة الحمامية الجهازية (يُسمى أيضًا "الذئبة" "SLE").

- إذا كنت مصابًا بمرض السكري (ارتفاع مستوى السكر في الدَّم).

- إذا كنت مصابًا بارتفاع مستويات الكوليسترول أو الدهون الثلاثية في دمك.

- إذا تعرَّضت لتفاعلات جلدية مثل: الطفح الجلدي بعد التعرض لأشعة الشمس.

- إذا أُصِبت بتفاعلات حساسية تجاه أدوية علاج ارتفاع ضغط الدَّم الأخرى أو مُدِرات البول (نوع من الأدوية ويُعرف أيضًا باسم: "أقراص الماء")، لا سيِّما إذا كنت تُعاني من الربو والحساسية - إذا كنت مُصابًا بإعياء (قيء أو إسهال).

- إذا تعرَّضت لتورُّم، لا سيِّما بالوجه والحَلْق، أثناء تناوُل أدوية أخرى (بما في ذلك مثبطات الإنزيم المُحوِّل
للأنجيوتنسين). إذا أُصِبت بهذه الأعراض، فتوقف عن تناوُل عقار أربافاسك إتش سي تي واتصل بطبيبك فورًا.

يجب ألا تتناول عقار أربافاسك إتش سي تي ثانيةً.

- إذا تعرَّضت لدوخة و/أو إغماء أثناء العلاج بعقار أربافاسك إتش سي تي، فأخبِر طبيبك بأسرع ما يُمكِن.

-إذا كنت تعاني من انخفاض في الرؤية أو ألم في العين , يمكن أن تكون هذه أعراض تراكم السوائل في الطبقة الوعائية للعين (الانصباب المشيمي) أو زيادة الضغط في العين ويمكن ان تحدث في غضون ساعات او 6 اسابيع من تناول المستحضر.
- إذا كنت تعاني من تراكم للسوائل بين المشيمة (الطبقة التي تحتوي على الأوعية الدموية التي تغذي الشبكية) والصلبة , الغطاء الخارجي الأبيض للعين.  

- إذا كنت تتناول أيًّا من الأدوية التَّالية التي تُستَخدَم لعلاج ارتفاع ضغط الدَّم: - مثبط الإنْزيم المُحَوِّل للأَنْجيُوتَنْسينِ (على سبيل المثال: إنالابريل، ليزينوبريل، راميبريل)، لا سيما إذا كنت تُعاني من مشاكل بالكُلى متعلقة بمرض السُّكري. - أليسكيرين. قد يُجري لك طبيبك فحصًا لوظائف الكُلى وضغط الدَّم وكمية الكهارل (على سبيل المثال: البوتاسيوم) في دمك على فترات منتظمة. انظر أيضًا المعلومات تحت عنوان: "لا تتناول عقار أربافاسك إتش سي تي".

إذا كان أيٌّ من ذلك ينطبق عليك، فيُرجى التحدُّث إلى طبيبك.

الأطفال والمراهقون

لا يُنصح بتناوُل عقار أربافاسك إتش سي تي في الأطفال والمراهقين الذين تقل أعمارهم عن ١٨ عامًا.

كبار السن ( من عمر ٦٥ عامًا فأكثر)

يُمكِن أن يُستَخدَم عقار أربافاسك إتش سي تي من قِبَل الأشخاص بعُمْر ٦٥ عامًا فأكثر بالجرعة نفسها الخاصة بغيرهم من البالغين وبنفس الطريقة التي تناولوا بها بالفعل المواد الثلاثة (أملوديبيت وفالسارتان
وهيدروكلوروثيازيد). يجب خضوع المرضى من كبار السن، لفحص ضغط الدَّم بصفة منتظمة.

تناوُل عقار أربافاسك إتش سي تي مع أدوية أخرى

يُرجى إبلاغ الطبيب أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.

قد يحتاج طبيبك لتغيير جرعتك و/أو اتخاذ احتياطات أخرى: وفي بعض الحالات، قد تكون مضطرًّا للتوقف عن تناول أحد الأدوية. يُعَد هذا مُهِمًّا بشكل خاص إذا كنت تستخدم أيًّا من الأدوية المُدرَجة أدناه:

لا تتناوله بمصاحبة:

∙ الليثيوم (دواء يُستَخدم لعلاج بعض أنواع من الاكتئاب).

∙ الأدوية أو المواد التي قد تُزيد كمية البوتاسيوم في دمك. تشمل هذه الأدوية مكملات البوتاسيوم، أو بدائل الملح التي تحتوي على البوتاسيوم، أو الأدوية الموفرة للبوتاسيوم والهيبارين.

∙ إذا كنت تتناول مثبط الإنْزيم المُحَوِّل للأَنْجيُوتَنْسينِ أو أليسكيرين (انظر أيضًا المعلومات الواردة تحت العناوين: "لا تتناول عقار أربافاسك إتش سي تي"، و"تحذيرات واحتياطات").

يجب توخي الحذر:

∙ الكحوليات وأقراص النوم وأدوية التخدير (الأدوية التي تسمح بخضوع المرضى للجراحة والإجراءات الأخرى).

∙ أمانتادين (علاج لمرض باركنسون، يستخدم أيضًا لعلاج أو الوقاية من أمراض فيروسية معينة).

الأدوية المضادة للكولين (الأدوية التي تُستخدَم لعلاج العديد من الاضطرابات مثل: تقلصات المعدة والأمعاء وتقلص المثانة والربو ودوار الحركة وتشنجات العضلات ومرض باركنسون وكعامل مساعد في التخدير).

الأدوية المضادة للتشنُّجات والأدوية المُثبِّتة للحالة المزاجية التي تُستَخدَم لعلاج الصَّرَع والاضْطِّراب ثنائي القطب (على سبيل المثال: كَرْبامازِيبين، فينوباربيتال، فينيتوين، فوسفينيتوين، بريميدون).

كولستيرامين أو كوليستيبول أو الراتنجات الأخرى (مواد تُستَخدَم بشكل أساسي لعلاج المستويات المرتفعة من الدهون في الدَّم).

∙ سيمفاستاتين (دواء يُستَخدَم للتحكم في مستويات الكوليسترول في المرتفعة).

∙ سيكلوسبورين (دواء يُستَخدَم في عمليات الزَّرع لمنع رفض العضو أو لحالات أخرى، على سبيل المثال: التهاب المفاصل أو التهاب الجلد التَّأتُّبِيّ).

∙ الأدوية السامة للخلايا (التي تستخدم لعلاج السرطان)، مثل: ميثوتريكسات أو سيكلوفوسفاميد.

∙ ديجوكسِين أو جليكوزيدات الديجيتاليس (الأدوية التي تُستخدَم لعلاج مشاكل القلب).

∙ فيراباميل، ديلتِيازيم (أدوية القلب).

∙ صبغات التباين المحتوية على اليود (عوامل تُستخدَم لفحوصات الأشعة).

∙ أدوية علاج مرض السُّكَّري (الأدوية التي يتم تناوُلها عن طريق الفم مثل: ميتفورمين أو الأنسولين).

∙ أدوية علاج النقرس: مثل ألوبيورينول.

∙ الأدوية التي قد تزيد من مستويات السكر في الدَّم (حاصرات مستقبلات البيتا، الديازوكسيد).

∙ الأدوية التي قد تُسبب "التفاف النقاط (إحدى العلامات برسم القلب)" (عدم انتظام ضربات القلب)، مثل: الأدوية المضادة لاضطرابات النظم القلبي وبعض مضادات الذهان.

∙ الأدوية التي قد تقلل كمية الصوديوم في دمك، مثل: مضادات الاكتئاب، مضادات الذهان، مضادات الصرع.

∙ الأدوية التي قد تخفض كمية البوتاسيوم في دمك، مثل: مدرات البول (أقراص الماء)، الكورتيكوستيرويدات، المُليّنات، أَمْفُوتيريسين أو البنيسللين جي.

∙ أدوية لرفع ضغط الدَّم، مثل: نورادرينالين أو أدرينالين.

∙ الأدوية التي تُستَخدم لعلاج فيروس نقص المناعة البشري/ الإيدز (على سبيل المثال: ريتونافير، إندينافير، نيلفينافير).

∙ أدوية تستخدم لعلاج الالتهابات الفطرية (مثل: كيتوكونازول وإتراكونازول).

∙ الأدوية التي تُستَخدَم لعلاج تقرُّح والتهاب المريء (كَرْبينُوكْسُولُون).

∙ الأدوية التي تخفف الألم والالتهاب خاصة مضادات الالتهاب غير الستيرويدية بما في ذلك مثبطات سيكلو أوكسجينيز-٢ (COX-2) الانتقائية.

∙ مُرخيات العضلات (أدوية لإرخاء العضلات تُستَخدَم أثناء العمليات الجراحية).

∙ النِّتْروجليسِرين والنترات الأخرى، أو المواد الأخرى التي تُسمى: "مُوسِّعات الأوعية الدَّموية".

∙ أدوية أخرى لعلاج ارتفاع ضغط الدَّم، بما في ذلك ميثيل دوبا.

∙ ريفامبيسين (يستخدم في علاج السل).

∙ نبتة سانت جونز.

∙ دانتُرولِين (تسريب لعلاج الاضطرابات الشَّديدة في درجة حرارة الجسم).

∙ فيتامين "د" العلاجي ومكملات الكالسيوم.

تناوُل عقار أربافاسك إتش سي تي مع الأطعمة والمشروبات والكحوليات

يجب ألا يتناول عصير الجريب فروت والجريب فروت من قِبل الأشخاص الذين يتناولون عقار أربافاسك إتش سي تي. هذا لأن الجريب فروت وعصير الجريب فروت يُمكِن أن يُؤديا إلى ارتفاع في مستويات المادة الفعَّالة، أملوديبين في الدَّم، الأمر الذي يُمكِن أن يُسبب ارتفاعًا غير مُتوقَّع في تأثير عقار أربافاسك إتش سي تي الخافض لضغط الدَّم. تحدَّث إلى طبيبك قبل تناول الكحوليات. قد تُؤدي الكحوليات إلى هبوط ضغط الدَّم لديك بشكل كبير للغاية و/أو تُزيد احتمالية حدوث دوخة أو إغماء.

الحمل والرضاعة الطبيعية

الحمل

يجب عليكِ إخبار طبيبكِ إذا كنتِ تعتقدين أنكِ حامل أو قد تصبحين حاملاً. سينصحكِ طبيبكِ في العادة بالتوقف عن تناوُل عقار أربافاسك إتش سي تي قبل أن تصبِحي حاملاً أَو بِمجرّد أَن تعلمي بِأنكِ حامل، وسينصحك بِتناوُل دواء آخر بدلاً من عقار أربافاسك إتش سي تي. لا ينصح باستخدام عقار أربافاسك إتش سي تي في وقت مبكر من الحمل، ويجب ألا يتم تناوله إذا تعدى حملك الشهر الثالث؛ حيث إنه قد يُسبب أضرار خطيرة لطفلك إذا تم استخدامه بعد الشهر الثالث من الحمل. أخبري طبيبك إذا كنتِ تُرضعين طفلك طبيعيًّا، أو على وشك البدء في إرضاعه طبيعيًّا. لا يُوصى باستخدام أربافاسك إتش سي تي من قِبل الأمهات اللاتي ترضعن طبيعيًّا، وقد يختار لكِ طبيبكِ علاجًا آخر إذا كنت ترغبين في الرضاعة الطبيعيَّة، خاصة إذا كان طفلك حديث الولادة، أو مبتسرًا. استشيري الطبيب أو الصيدلي الخاص بك قبل تناول أي دواء.

الرضاعة الطبيعية

أخبري طبيبكِ إذا كنتِ تُرضعين طفلك طبيعيًّا، أو على وشك البدء في إرضاعه طبيعيًّا. لا يوصى باستخدام أربافاسك إتش سي تي من قبل الأمهات اللاتي ترضعن طبيعيًِّا، وقد يختار لكِ طبيبكِ علاجًا آخر إذا كنتِ
ترغبين في الرضاعة الطبيعيَّة، خاصة إذا كان طفلك حديث الولادة، أو مبتسرًا.

استشيري الطبيب أو الصيدلي الخاص بك قبل تناول أي دواء.

القيادة واستخدام الآلات

قد يجعلك هذا الدَّواء تشعر بالدوخة أو النُّعاس أو الغثيان أو الصُّداع. إذا واجهت هذه الأعراض، فلا تمارس القيادة أو تستخدم الأدوات أو الآلات.

https://localhost:44358/Dashboard

تناوَل دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. يُرجى مراجعة طبيبك إذا لم تكن متأكدًا من كيفية التناول. سيُساعدك هذا في الحصول على أفضل النتائج ولتقليل خطر الإصابة بالآثار الجانبية.

الجرعة المُعتادة من أربافاسك إتش سي تي هي قرص واحد في اليوم.

- حاول أن تتناول القرص في نفس الوقت من كل يوم. الصباح هو الوقت الأفضل.

- ابتلع الأقراص كاملة مع كوب من الماء.

- يمكنك تناول أربافاسك إتش سي تي مع الطعام أو دونه. لا تتناول عقار أربافاسك إتش سي تي مع الجريب فروت أو عصير الجريب فروت.

- قد يصف لك طبيبك جرعة أعلى أو أقل وفقًا إلى كيفية استجابتك للعلاج.

- لا تتجاوز الجرعات التي تم وصفها لك.

إذا تناولت كمية أكثر مما يجب من أربافاسك إتش سي تي

إذا تناولت بطريق الخطأ كمية كبيرة للغاية من عقار أربافاسك إتش سي تي، فتحدَّث إلى الطبيب فورًا. قد تحتاج إلى العناية الطبية.

إذا أغفلت تناوُل عقار أربافاسك إتش سي  تي

إذا أغفلت تناول جرعة فتناولها بمجرد تذكرها وتناول الجرعة التَّالية في موعدها المعتاد. إذا اقترب موعد جرعتك التَّالية فما عليك سوى تناوُل القرص التَّالي في الوقت المُعتاد. لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها.

إذا توقفت عن تناول عقار أربافاسك إتش سي تي

التَّوقف عن تناوُل أربافاسك إتش سي تي قد يُسبب لك تفاقم ارتفاع ضغط الدَّم. لا تتوقف عن تناول دوائك ما لم  يخبرك الطبيب بذلك.

تناول دائمًا هذا الدَّواء، حتى إذا كنت تشعر أنك على ما يُرام

الأشخاص المصابون بارتفاع ضغط الدَّم غالبًا لا يُلاحظون أي علامات على هذه المشكلة. قد يشعر الكثير بأن الأمور طبيعية تمامًا. من الهَام للغاية أن تتناول هذا الدَّواء بالضبط كما أخبرك طبيبك؛ للحصول على أفضل نتائج ولتقليل خطر الإصابة بآثار جانبية. حافظ على مواعيدك مع الطبيب حتى إذا كنت تشعر بأنك على ما يُرام.

إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدواء، فاستشر الطبيب أو الصيدلي الخاص بك.

مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.

بالنسبة لأي تركيبة تحتوي على ثلاث مواد فعَّالة، لا يُمكِن استبعاد حدوث الآثار الجانبية المصاحبة لكل مُكوِّن من الثلاثة مُكوِّنات. مُدرَج أدناه الآثار الجانبية التي تم الإبلاغ عنها مع عقار أربافاسك إتش سي تي أو
إحدى مواده الفعَّالة الثلاث (أملوديبين وفالسارتان وهيدروكلوروثيازيد)، وقد تحدث مع استخدام عقار
أربافاسك إتش سي تي.

بعض الآثار الجانبية قد تكون خطيرة وتحتاج إلى عناية طبية فورية:

أخبر طبيبك فورًا إذا كنت تواجه أيًّا من الآثار الجانبية الخطيرة التَّالية بعد تناول هذا الدَّواء:

 

شائعة (قد تُؤثر على ما يصل إلى شخص واحد من كل ١٠ أشخاص):

∙ دوخة.

∙ انخفاض ضغط الدَّم (الشعور بالإغماء، الشعور بدوار بالرَّأس، فقدان الوعي المفاجئ).

غير شائعة: (قد تُؤثر على ما يصل إلى شخص واحد من بين كل ١٠٠ شخص):

∙ انخفاض إخراج البول بشكل شديد (ضعف وظائف الكلى).

نادرة (قد تُؤثر في ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص):

∙ نزيف تلقائي.

∙ ضربات قلب غير منتظمة.

∙ اضطراب في الكبد.

نادرة جدًّا (قد تُؤثر في ما يصل إلى ١ من كل ١٠٠٠٠ شخص):

∙ أزيز مفاجئ بالصدر، ألم في الصدر، ضيق أو صعوبة بالتَّنفس.

∙ تورم الجفنين أو الوجه أو الشفتين.

∙ تورُّم اللسان والحَلْق مما قد يُسبب صعوبة كبيرة في التَّنفس.

∙ تفاعلات حساسية شديدة تشمل: الطفح الجلدي الشديد، الشرى (الأرتكاريا)، احمرار جلد الجسم بالكامل، حكة شديدة، ظهور نفطات، تقشُّر وتورُّم الجلد، التهاب الأغشية المخاطية (متلازمة ستيفنز جونسون) أو غيرها من تفاعلات الحساسية.

∙ نوبة قلبية.

∙ التهاب البنكرياس، الذي قد يُسبب ألمًا شديدًا بالبطن والظهر مصحوبًا بشعور بالتوعُّك الشديد.

∙ ضعف، تكدُّم، حُمى وعدوى متكررة الحدوث.

∙ تصلُّب (تيبُّس).

تشمل الآثار الجانبية الأخرى التالي:

شائعة جدًا (قد تُؤثر على أكير من ١ من بين كل ١٠ أشخاص):

∙ انخفاض مستوى البوتاسيوم بالدم.

∙ ارتفاع نسبة الدهون في الدم.

شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل ١٠ أشخاص):

∙ النُّعاس.

∙ خفقان (إدراك ضربات القلب).

∙ احمرار الجلد.

∙ تورُّم الكاحل (وذمة).

∙ ألم بالبطن.

∙ شعور غير مريح بالمعدة بعد تناول الوجبات.

∙ تعب.

∙ الصداع.

∙ التبوُّل بصفة متكررة.

∙ ارتفاع مستوى حمض اليوريك في الدم.

∙ انخفاض مستوى الماغنسيوم بالدم.

∙ انخفاض مستوى الصوديوم في الدم.

∙ دوخة، إغماء عند الوقوف.

∙ انخفاض الشهية.

∙ غثيان وقيء.

∙ طفح جلدي مصحوب بحكة وأنواع أخرى من الطفح الجلدي.

∙ عدم القدرة على الحصول على انتصاب أو المحافظة عليه.

غير شائعة: (قد تُؤثر على ما يصل إلى شخص واحد من بين كل ١٠٠ شخص):

∙  تسارع ضربات القلب.

∙ شعور بالدوران.

∙ اضطراب الرؤية.

∙ ضيق بالمعدة.

∙ ألم في الصدر.

∙ زيادة مستوى النيتروجين يوريا والكرياتينين وحمض اليوريك في الدم.

∙ ارتفاع مستوى الكالسيوم، الدهون أو الصوديوم في الدم.

∙ انخفاض مستوى البوتاسيوم بالدَّم.

∙ وجود رائحة للنفس.

∙ الإسهال.

∙ جفاف الفم.

∙ زيادة الوزن.

* فقدان الشهية.

∙ اضطراب حاسة التذوُّق.

∙ آلام الظهر.

∙ تورم المفاصل.

∙  ألم / ضعف / تقلصات بالعضلات.

∙ ألم بالأطراف.

∙ عدم القدرة على الوقوف أو المشي بشكل طبيعي.

∙ ضعف.

∙ اضطرابات التَّنسيق.

∙ دوخة عند الوقوف أو بعد ممارسة التمارين.

∙ نقص الطاقة والضعف.

∙ اضطرابات النوم.

∙ وخز أو تنميل.

∙ اعتلال الأعصاب.

∙ فقدان الوعي المفاجئ أو المؤقت.

∙ انخفاض ضغط الدم عند الوقوف.

∙ سعال.

∙ ضيق التَّنَفُّس.

∙ تهيُّج الحلق.

∙ فرط التَّعرق.

∙ حكة بالجلد.

∙ تورُّم واحمرار وألم بطول الوريد.

∙ احمرار الجلد.

∙ ارتجاف.

∙ تغيرات مزاجية.

∙ القلق.

∙ الاكتئاب.

∙ عدم القدرة على النوم (أرق).

∙ اضطرابات التَّذوق.

∙ الإغماء.

∙ فقدان الإحساس بالألم.

∙ اضطرابات بصرية.

∙ ضعف البصر.

∙ "رنين" في الأذنين (طنين).

∙ عطس/ سيلان الأنف ناجم عن التهاب في بطانة الأنف (التهاب الأنف).

∙ تغير في طبيعة الأمعاء المعتادة.

∙ عسر الهضم.

∙ تساقط الشعر.

∙ حكة بالجلد.

∙ تغيير لون الجلد.

∙ اضطراب في التبول.

∙ زيادة الحاجة إلى التبول أثناء الليل.

∙ زيادة عدد مرات التبول.

∙ الشعور بالانزعاج أو تضخم الثدي لدى الرجال.

∙ ألم.

• شعور بالإعياء (توعك).

∙ انخفاض الوزن.

نادرة (قد تؤثر في ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص):

∙ انخفاض مستوى الصفائح الدموية (أحيانًا مع نزيف أو كدمات أسفل الجلد).

∙ وجود سكر بالبول.

∙ ارتفاع مستوى السكر في الدم.

∙ تفاقم الحالة الاستقلابية لمرض السكري.

∙ انتفاخ البطن.

∙ إمساك.

∙ اضطرابات الكبد التي قد تحدث مع اصفرار الجلد والعينين، أو بول داكن اللون (فقر الدم الانحلالي).

∙ زيادة حساسية الجلد تجاه أشعة الشمس.

∙ بقع بنفسجية على الجلد.

∙ اضطرابات الكلى.

∙ ارتباك.

نادرة جدًّا (قد تؤثر في ما يصل إلى ١ من كل ١٠٠٠٠ شخص):

∙ انخفاض عدد كريات الدَّم البيضاء:

∙ انخفاض الصفائح الدَّموية الذي قد يُؤدي إلى تكدُّم غير مُعتاد أو سهولة النزيف (تلف خلايا الدَّم الحمراء).

∙ تورم اللثة.

∙ انتفاخ البطن (التهاب المعدة).

∙ التهاب الكبد.

∙ اصفرار الجلد (يرقان).

∙ زيادة إنزيمات الكبد مما قد يكون له تأثير على نتائج بعض الاختبارات الطبية.

∙ زيادة توتر العضلات.

∙ التهاب الأوعية الدموية المصحوب غالبًا بطفح جلدي.

∙ الحساسية للضوء.

∙ اضطرابات تشمل: التصلُّب، الارتعاش و/أو اضطرابات الحركة.

حُمى، التهاب الحَلْق أو قُرَح الفم، عدوى تحدث بشكل أكثر تكرارًا (نقص أو انخفاض مستوى خلايا الدَّم البيضاء).

∙ شحوب الجلد، تعب، عُسْر التََّنَفُّس، بول داكن اللون (فقر الدَّم الانحلالي، تكسير خلايا الدَّم الحمراء غير الطبيعي سواء في الأوعية الدموية أو في أي مكان آخر بالجسم).

∙ ارتباك، تعب، انتفاض وتقلص العضلات، تنفس سريع (قلوية ناتجة عن نقص كلوريد الدم).

∙ ألم شديد أعلى المعدة (التهاب البنكرياس).

∙ صعوبة في التَّنفس، مع حمى، سعال، أزيز بالصدر، ضيق التنفس (أزمة تنفسية تشمل الالتهاب الرئوي والوذمة الرئوية).

∙ طفح جلدي بالوجه، ألم بالمفاصل، اضطراب بالعضلات، حُمى (الذئبة الحمراء الجهازية).
∙ التهاب الأوعية الدَّموية المصحوب بأعراض مثل: طفح جلدي، بقع حمراء تميل إلى القرمزي، حُمى (التهاب الأوعية الدموية).

∙ مرض شديد بالجلد يُسبب طفحًا جلديًّا، احمرار الجلد، نفطات بالشفتين أو العينين أو الفم، تقشُّر الجلد، حُمى (انحلال البشرة النخري التَّسَمُّمِيّ).

غير معروفة: (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة):

∙ تغيُّرات في نتائج اختبارات الدَّم لفحص وظائف الكُلى، ارتفاع مستوى البوتاسيوم في الدَّم، انخفاض مستوى خلايا الدَّم الحمراء.

∙ نتائج غير طبيعية لاختبار خلايا الدَّم الحمراء.

∙ انخفاض مستويات أحد أنواع خلايا الدم البيضاء والصفائح الدموية.

∙ ارتفاع مستوى الكرياتينين في الدم.

∙ نتائج غير طبيعية باختبارات وظائف الكبد.

∙ انخفاض إخراج البول بشكل شديد.

∙ التهاب الأوعية الدموية.

∙ ضعف، كدمات وعدوى متكررة (فقر الدَّم اللاتنسجي).

∙ انخفاض في الرؤية أو ألم في عينيك بسبب ارتفاع الضغط (علامات مُحتمَلة لتراكم السوائل في الطبقة الوعائية للعين او انسداد الزاوية الحادة).

∙ ضيق التََّنفُس.

∙ انخفاض إخراج البول بشكل شديد (علامات مُحتمَلة للإصابة باضطراب أو فشل الكُلى).

∙ مرض شديد بالجلد يُسبب طفحًا جلديًّا، احمرار الجلد، نفطات بالشفتين أو العينين أو الفم، تقشر الجلد، حُمى (احمرار متعدد الأشكال).

∙ تقلصات عضلية.

∙ حمى.

∙ ظهور نفطات على الجلد (علامة على حالة تُسمى التهاب الجلد الفقاعي).

• سرطان الجلد والشفة (سرطان الجلد الغير ميلانيني).
• انصباب المشيمية (تراكم غير طبيعي للسوائل في المنطقة فوق المشيمية).
 

∙ يُحفَظ بعيدًا عن متناول ورؤية الأطفال.

∙ يُحفَظ في درجة حرارة أقل من 30 درجة مئوية.

∙ لا تستعمل عقار أربافاسك إتش سي تي بعد تاريخ انتهاء الصلاحية المدون على العبوة والشريط بعد كلمة "EXP"، يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.

∙ لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. سوف تُساعد هذه الإجراءات في الحفاظ على البيئة.

المواد الفعَّالة هي:

يحتوي عقار أربافاسك إتش سي تي (١٦٠/٥/12.5) على فالسارتان ١٦٠ ملج، بيزيلات الأملوديبين ٥ ملج وهيدروكلوروثيازيد 12.5 ملج

يحتوي عقار أربافاسك إتش سي تي (١٦٠/٥/٢٥) على فالسارتان ١٦٠ ملج، بيزيلات الأملوديبين ٥ ملج
وهيدروكلوروثيازيد ٢٥ ملج

يحتوي عقار أربافاسك إتش سي تي (١٦٠/ ١٠/12.5) على فالسارتان ١٦٠ ملج، بيزيلات الأملوديبين ١٠ ملج وهيدروكلوروثيازيد 12.5 ملج

يحتوي عقار أربافاسك إتش سي تي (١٦٠/ ١٠/٢٥) على فالسارتان ١٦٠ ملج، بيزيلات الأملوديبين ١٠ ملج وهيدروكلوروثيازيد ٢٥ ملج

المكونات الأخرى هي: سليلوز دقيق التَّبلور، كروسبوفيدون، ثاني أكسيد السيليكون الغروي، ستيرات الماغنسيوم، أوبادري.

عقار أربافاسك إتش سي تي ١٦٠/٥/12.5 ملج عبارة عن أقراص بيضاء اللون وبيضاوية الشكل وثنائية التحدُّب منقوش على أحد وجهيها "SJ523".

عقار أربافاسك إتش سي تي 1٦٠/٥/٢٥ ملج عبارة عن أقراص صفراء اللون وبيضاوية الشكل وثنائية التحدُّب منقوش على أحد وجهيها "SJ527".

عقار أربافاسك إتش سي تي ١٦٠/ ١٠/12.5 ملج عبارة عن أقراص مُغلَّفة ذات لون أصفر شاحب وبيضاوية الشكل وثنائية التحدُّب منقوش على أحد وجهيها "SJ525"

عقار أربافاسك إتش سي تي ١٦٠/ ١٠/12.5 ملج عبارة عن أقراص مُغلَّفة ذات لون أصفر مائل إلى البني وبيضاوية الشكل وثنائية التحدُّب منقوش على أحد وجهيها "SJ531".

تحتوي العبوة على ٢٨ قرصا مغلفا (4 شرائط , كل شريط يحتوي على 7 أقراص).

شركة ساجا للأدوية

الشركة السعودية اليابانية للأدوية، شركة محدودة

جدة – المملكة العربية السعودية

 

للإبلاغ عن أية آثار جانبية:
• المملكة العربية السعودية
- المركز الوطني للتيقظ والسلامة الدوائية
- مركز اتصال هيئة الغذاء والدواء : ١٩٩٩٩
npc.drug@sfda.gov.sa 
https://ade.sfda.gov.sa 
• دول مجلس التعاون الخليجي الأخرى:
يُرجى التواصل مع السلطات المعنية المختصة في كل بلد
 

أبريل/2022
 Read this leaflet carefully before you start using this product as it contains important information for you

Arbavasc HCT film-coated tablets

Arbavasc HCT F/C Tablet available in four strengths: • Arbavasc HCT (160/5/12.5) contains Valsartan 160mg, Amlodipine 5mg (as Besylate) and Hydrochlorothiazide 12.5 mg • Arbavasc HCT (160/5/25) contains Valsartan 160mg, Amlodipine 5mg and Hydrochlorothiazide 25 mg • Arbavasc HCT (160/10/12.5) contains Valsartan 160mg, Amlodipine 10mg and Hydrochlorothiazide 12.5 mg • Arbavasc HCT (160/10/25) contains Valsartan 160mg, Amlodipine 10mg and Hydrochlorothiazide 25 mg Arbavasc HCT Film-coated Tablets For the full list of excipients, see section 6.1

Film Coated Tablet

Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is
adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT),
taken either as three single-component formulations or as a dual-component and a single-component
formulation


 


Posology
The recommended dose of Arbavasc HCT is one tablet per day, to be taken preferably in the morning.
Before switching to Arbavasc HCT patients should be controlled on stable doses of the
monocomponents taken at the same time. The dose of Arbavasc HCT should be based on the doses of
the individual components of the combination at the time of switching.
The maximum recommended dose of Arbavasc HCT is 10 mg/320 mg/25 mg.
Special populations
Renal impairment
Due to the hydrochlorothiazide component, Arbavasc HCT is contraindicated for use in patients with
anuria (see section 4.3) and in patients with severe renal impairment (glomerular filtration rate (GFR)
<30 ml/min/1.73 m2) (see sections 4.3, 4.4 and 5.2).
No adjustment of the initial dose is required for patients with mild to moderate renal impairment (see
sections 4.4 and 5.2).
Hepatic impairment
Due to the valsartan component, Arbavasc HCT is contraindicated in patients with severe hepatic
impairment (see section 4.3). In patients with mild to moderate hepatic impairment without
cholestasis, the maximum recommended dose is 80 mg valsartan and therefore Arbavasc HCT is not
suitable in this group of patients (see sections 4.3, 4.4 and 5.2). Amlodipine dose recommendations
have not been established in patients with mild to moderate hepatic impairment. When switching
eligible hypertensive patients (see section 4.1) with hepatic impairment to Arbavasc HCT, the lowest
available dose of the amlodipine component should be used.
Heart failure and coronary artery disease
There is limited experience with the use of Arbavasc HCT, particulary at the maximum dose, in
patients with heart failure and coronary artery disease. Caution is advised in patients with heart failure
and coronary artery disease, particularly at the maximum dose of Arbavasc HCT, 10 mg/320 mg/25
mg.
Elderly (age 65 years or over)
Caution, including more frequent monitoring of blood pressure, is recommended in elderly patients,
particularly at the maximum dose of Arbavasc HCT, 10 mg/320 mg/25 mg, since available data in this
patient population are limited. When switching eligible elderly hypertensive patients (see section 4.1)
to Arbavasc HCT, the lowest available dose of the amlodipine component should be used.
Paediatric population
There is no relevant use of Arbavasc HCT in the paediatric population (patients below age 18 years)
for the indication of essential hypertension.
Method of administration
Oral use.
Arbavasc HCT can be taken with or without food.
The tablets should be swallowed whole with some water, at the same time of the day and preferably in
the morning


 


− Hypersensitivity to the active substances, to other sulphonamide derivatives, to dihydropyridine derivatives, or to any of the excipients listed in section 6.1. − Second and third trimesters of pregnancy (see sections 4.4 and 4.6). − Hepatic impairment, biliary cirrhosis or cholestasis. − Severe renal impairment (GFR <30 ml/min/1.73 m2), anuria and patients undergoing dialysis. − Concomitant use of Arbavasc HCT with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 ml/min/1.73 m2) (see sections 4.5 and 5.1). − Refractory hypokalaemia, hyponatraemia, hypercalcaemia, and symptomatic hyperuricaemia. − Severe hypotension. − Shock (including cardiogenic shock). − Obstruction of the outflow tract of the left ventricle (e.g. hypertrophic obstructive cardiomyopathy and high grade aortic stenosis). − Haemodynamically unstable heart failure after acute myocardial infarction

The safety and efficacy of amlodipine in hypertensive crisis have not been established.
Sodium- and/or volume-depleted patients
Excessive hypotension, including orthostatic hypotension, was seen in 1.7% of patients treated with the
maximum dose of Arbavasc HCT (10 mg/320 mg/25 mg) compared to 1.8% of
valsartan/hydrochlorothiazide (320 mg/25 mg) patients, 0.4% of amlodipine/valsartan (10 mg/320 mg)
patients, and 0.2% of hydrochlorothiazide/amlodipine (25 mg/10 mg) patients in a controlled trial in
patients with moderate to severe uncomplicated hypertension.
In sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics,
symptomatic hypotension may occur after initiation of treatment with Arbavasc HCT. Arbavasc HCT
should be used only after correction of any pre-existing sodium and/or volume depletion.
If excessive hypotension occurs with Arbavasc HCT, the patient should be placed in the supine position
and, if necessary, given an intravenous infusion of normal saline. Treatment can be continued once
blood pressure has been stabilised.
Serum electrolyte changes
Amlodipine/valsartan/hydrochlorothiazide
In the controlled trial of Arbavasc HCT, the counteracting effects of valsartan 320 mg and
hydrochlorothiazide 25 mg on serum potassium approximately balanced each other in many patients. In
other patients, one or the other effect may be dominant. Periodic determinations of serum electrolytes to
detect possible electrolyte imbalance should be performed at appropriate intervals.
Periodic determination of serum electrolytes and potassium in particular should be performed at
appropriate intervals to detect possible electrolyte imbalance, especially in patients with other risk
factors such as impaired renal function, treatment with other medicinal products or history of prior
electrolyte imbalances.
Valsartan
Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing
potassium, or other medicinal products that may increase potassium levels (heparin, etc.) is not
recommended. Monitoring of potassium should be undertaken as appropriate.
Hydrochlorothiazide
Treatment with Arbavasc HCT should only start after correction of hypokalaemia and any coexisting
hypomagnesaemia. Thiazide diuretics can precipitate new onset hypokalaemia or exacerbate pre
existing hypokalaemia. Thiazide diuretics should be administered with caution in patients with
conditions involving enhanced potassium loss, for example salt-losing nephropathies and prerenal
(cardiogenic) impairment of kidney function. If hypokalaemia develops during hydrochlorothiazide
therapy, Arbavasc HCT should be discontinued until stable correction of the potassium balance.
Thiazide diuretics can precipitate new onset hyponatraemia and hypochloroaemic alkalosis or
exacerbate pre-existing hyponatraemia. Hyponatraemia, accompanied by neurological symptoms
(nausea, progressive disorientation, apathy) has been observed. Treatment with hydrochlorothiazide
should only be started after correction of pre-existing hyponatraemia. In case severe or rapid
hyponatraemia develops during Arbavasc HCT therapy, the treatment should be discontinued until
normalisation of natraemia.
All patients receiving thiazide diuretics should be periodically monitored for imbalances in electrolytes,
particularly potassium, sodium and magnesium.
Renal impairment


 

Thiazide diuretics may precipitate azotaemia in patients with chronic kidney disease. When Arbavasc
HCT is used in patients with renal impairment periodic monitoring of serum electrolytes (including
potassium), creatinine and uric acid serum levels is recommended. Arbavasc HCT is contraindicated in
patients with severe renal impairment, anuria or undergoing dialysis (see section 4.3).
No dose adjustment of Arbavasc HCT is required for patients with mild to moderate renal impairment
(GFR ≥30 ml/min/1.73 m2).
Renal artery stenosis
Arbavasc HCT should be used with caution to treat hypertension in patients with unilateral or bilateral
renal artery stenosis or stenosis to a solitary kidney since blood urea and serum creatinine may increase
in such patients.
Kidney transplantation
To date there is no experience of the safe use of Arbavasc HCT in patients who have had a recent kidney
transplantation.
Hepatic impairment
Valsartan is mostly eliminated unchanged via the bile. The half-life of amlodipine is prolonged and
AUC values are higher in patients with impaired liver function; dose recommendations have not been
established. In patients with mild to moderate hepatic impairment without cholestasis, the maximum
recommended dose is 80 mg valsartan, and therefore, Arbavasc HCT is not suitable in this group of
patients (see sections 4.2, 4.3 and 5.2).
Angioedema
Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling of
the face, lips, pharynx, and/or tongue, has been reported in patients treated with valsartan. Some of these
patients previously experienced angioedema with other medicinal products including ACE inhibitors.
Arbavasc HCT should be discontinued immediately in patients who develop angioedema and should not
be re-administered.
Heart failure and coronary artery disease/post-myocardial infarction
As a consequence of the inhibition of the renin-angiotensin-aldosterone system, changes in renal
function may be anticipated in susceptible individuals. In patients with severe heart failure whose renal
function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with ACE
inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive
azotaemia and (rarely) with acute renal failure and/or death. Similar outcomes have been reported with
valsartan. Evaluation of patients with heart failure or post-myocardial infarction should always include
assessment of renal function.


 

In a long-term, placebo-controlled study (PRAISE-2) of amlodipine in patients with NYHA (New York
Heart Association Classification) III and IV heart failure of non-ischaemic aetiology, amlodipine was
associated with increased reports of pulmonary oedema despite no significant difference in the incidence
of worsening heart failure as compared to placebo.
Calcium channel blockers, including amlodipine, should be used with caution in patients with
congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.
Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum
dose of Arbavasc HCT, 10 mg/320 mg/25 mg, since available data in these patient populations is
limited.
Aortic and mitral valve stenosis
As with all other vasodilators, special caution is indicated in patients with mitral stenosis or significant
aortic stenosis that is not high grade.
Pregnancy
Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless
continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to
alternative antihypertensive treatments which have an established safety profile for use in pregnancy.
When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if
appropriate, alternative therapy should be started (see sections 4.3 and 4.6).
Primary hyperaldosteronism
Patients with primary hyperaldosteronism should not be treated with the angiotensin II antagonist
valsartan as their renin-angiotensin system is not activated. Therefore, Arbavasc HCT is not
recommended in this population.
Systemic lupus erythematosus
Thiazide diuretics, including hydrochlorothiazide, have been reported to exacerbate or activate systemic
lupus erythematosus.
Other metabolic disturbances
Thiazide diuretics, including hydrochlorothiazide, may alter glucose tolerance and raise serum levels of
cholesterol, triglycerides and uric acid. In diabetic patients dosage adjustments of insulin or oral
hypoglycaemic agents may be required.
Due to the hydrochlorothiazide component, Arbavasc HCT is contraindicated in symptomatic
hyperuricaemia. Hydrochlorothiazide may raise the serum uric acid level due to reduced clearance of
uric acid and may cause or exacerbate hyperuricaemia as well as precipitate gout in susceptible patients.

Thiazides reduce urinary calcium excretion and may cause intermittant and slight elevation of serum
calcium in the absence of known disorders of calcium metabolism. Arbavasc HCT is contraindicated in
patients with hypercalcaemia and should only be used after correction of any pre-existing
hypercalcaemia. Arbavasc HCT should be discontinued if hypercalcaemia develops during treatment.
Serum levels of calcium should be periodically monitored during treatment with thiazides. Marked
hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued
before carrying out tests for parathyroid function.
Photosensitivity
Cases of photosensitivity reactions have been reported with thiazide diuretics (see section 4.8). If
photosensitivity reaction occurs during treatment with Arbavasc HCT, it is recommended to stop the
treatment. If a readministration of the diuretic is deemed necessary, it is recommended to protect
exposed areas to the sun or to artificial UVA.

Choroidal effusion, acute myopia and secondary angle-closure glaucoma:

Sulfonamide or sulfonamide derivative drugs can cause an idiosyncratic reaction resulting in choroidal effusion with visual field defect, transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue drug intake as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy

General
Caution should be exercised in patients who have shown prior hypersensitivity to other angiotensin II
receptor antagonists. Hypersensitivity reactions to hydrochlorothiazide are more likely in patients with
allergy and asthma.
Elderly (age 65 years or over)
Caution, including more frequent monitoring of blood pressure, is recommended in elderly patients,
particularly at the maximum dose of Arbavasc HCT, 10 mg/320 mg/25 mg, since available data in this
patient population are limited.
Dual blockade of the renin-angiotensin-aldosterone system (RAAS)
There is evidence that the concomitant use of ACE inhibitors, ARBs or aliskiren increases the risk of
hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade
of RAAS through the combined use of ACE inhibitors, ARBs or aliskiren is therefore not recommended
(see sections 4.5 and 5.1).


 

If dual blockade therapy is considered absolutely necessary, this should only occur under specialist
supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.
ACE inhibitors and ARBs should not be used concomitantly in patients with diabetic nephropathy

Non-melanoma skin cancer

An increased risk of non-melanoma skin cancer (NMSC) [basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)] with increasing cumulative dose of hydrochlorothiazide exposure has been observed in two epidemiological studies based on the Danish National Cancer Registry. Photosensitising actions of hydrochlorothiazide could act as a possible mechanism for NMSC.

Patients taking hydrochlorothiazide should be informed of the risk of NMSC and advised to regularly check their skin for any new lesions and promptly report any suspicious skin lesions. Possible preventive measures such as limited exposure to sunlight and UV rays and, in case of exposure, adequate protection should be advised to the patients in order to minimize the risk of skin cancer. Suspicious skin lesions should be promptly examined potentially including histological examinations of biopsies. The use of hydrochlorothiazide may also need to be reconsidered in patients who have experienced previous NMSC (see also section 4.8).


1.1    No formal interaction studies with other medicinal products have been performed with Arbavasc HCT. Thus, only information on interactions with other medicinal products that are known for the individual active substances is

provided in this section.

 

However, it is important to take into account that Arbavasc HCT may increase the hypotensive effect of other antihypertensive agents.

 

Concomitant use not recommended

 

Arbavasc HCT

individual component

Known interactions with the following agents

Effect of the interaction with other medicinal products

Valsartan and HCT

Lithium

Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, angiotensin II receptor antagonists including valsartan or thiazides. Since renal clearance of lithium is reduced by thiazides, the risk of lithium toxicity may presumably be increased further with Arbavasc HCT. Therefore careful monitoring of serum lithium concentrations is recommended during concomitant use.

Valsartan

Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels

If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, frequent monitoring of potassium plasma levels is advised.

 

Amlodipine

Grapefruit or grapefruit juice

Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients, resulting in increased blood pressure lowering effects.

 

Caution required with concomitant use

 

Arbavasc HCT

individual component

Known interactions with the following agents

Effect of the interaction with other medicinal products

Amlodipine

CYP3A4 inhibitors

 

(i.e. ketoconazole, itraconazole, ritonavir)

Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The clinical translation of these pharmacokinetic variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required.

CYP3A4

inducers (anticonvulsant agents [e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone], rifampicin, Hypericum perforatum[St. John's wort])

There is no data available regarding the effect of CYP3A4 inducers on amlodipine. The concomitant use of CYP3A4 inducers (e.g. rifampicin, Hypericum perforatum) may give a lower plasma concentration of amlodipine. Amlodipine should be used with caution together with CYP3A4 inducers.

Simvastatin

Co-administration of multiple doses of 10 mg amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. It is recommended to limit the dose of simvastatin to 20 mg daily in patients on amlodipine.

Dantrolene (infusion)

In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalaemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalaemia, it is recommended that the co- administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.

Valsartan and HCT

Non-steroidal anti- inflammatory drugs (NSAIDs), including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors), acetylsalicylic acid (>3 g/day), and non-selective NSAIDs

NSAIDS can attenuate the antihypertensive effect of both angiotensin II antagonists and hydrochlorothiazide when administered simultaneously. Furthermore, concomitant use of Arbavasc HCT and NSAIDs may lead to worsening of renal function and an increase in serum potassium. Therefore, monitoring of renal function at the beginning of the treatment is recommended, as well as adequate hydration of the patient.

Valsartan

Inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir)

The results of an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1 and of the hepatic efflux transporter MRP2. Co- administration of inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir) may increase the systemic exposure to valsartan.

HCT

Alcohol, barbiturates or narcotics

Concomitant administration of thiazide diuretics with substances that also have a blood pressure lowering effect (e.g. by reducing sympathetic central nervous system activity or direct vasodilatation) may potentiate orthostatic hypotension.

 

 

Amantadine

Thiazides, including hydrochlorothiazide, may increase the risk of adverse reactions caused by amantadine.

Anticholinergic agents and other medicinal products affecting gastric motility

The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g. atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. Conversely, it is anticipated that prokinetic substances such as cisapride may decrease the bioavailability of thiazide-type diuretics.

Antidiabetic agents (e.g. insulin and oral antidiabetic agents)

Thiazides may alter glucose tolerance. Dose adjustment of the antidiabetic medicinal product may be necessary.

Metformin

Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.

Beta blockers and diazoxide

Concomitant use of thiazide diuretics, including hydrochlorothiazide, with beta blockers may increase the risk of hyperglycaemia. Thiazide diuretics, including hydrochlorothiazide, may enhance the hyperglycaemic effect of diazoxide.

Ciclosporin

Concomitant treatment with ciclosporin may increase the risk of hyperuricaemia and gout-type complications.

Cytotoxic agents

Thiazides, including hydrochlorothiazide, may reduce the renal excretion of cytotoxic agents (e.g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.

Digitalis glycosides

Thiazide-induced hypokalaemia or hypomagnesaemia may occur as undesirable effects, favouring the onset of digitalis- induced cardiac arrhythmias.

Iodine contrasting agents

In case of diuretic-induced dehydration, there is an increased risk of acute renal failure, especially with high doses of iodine products. Patients should be re-hydrated before the administration.

Ion exchange resins

Absorption of thiazide diuretics, including hydrochlorothiazide, is decreased by cholestyramine or colestipol. This could result in sub-therapeutic effects of thiazide diuretics. However, staggering the dosage of hydrochlorothiazide and resin such that hydrochlorothiazide is administered at least 4 hours before or 4- 6 hours after the administration of resins would potentially minimise the interaction.

Medicinal products affecting serum potassium level

The hypokalaemic effect of hydrochlorothiazide may be increased by concomitant administration of kaliuretic diuretics, corticosteroids, laxatives, adrenocorticotropic hormone (ACTH), amphotericin, carbenoxolone, penicillin G and salicylic acid derivatives or antiarrhythmics. If these medicinal products are to be prescribed with the amlodipine /valsartan /hydrochlorothiazide combination, monitoring of potassium plasma levels is advised.

Medicinal products affecting serum sodium level

The hyponatraemic effect of diuretics may be intensified by concomitant administration of medicinal products such as antidepressants, antipsychotics, antiepileptics, etc. Caution is indicated in long-term administration of these medicinal products.

 

 

Medicinal products that could induce torsades de pointes

Due to the risk of hypokalaemia, hydrochlorothiazide should be administered with caution when associated with medicinal products that could induce torsades de pointes, in particular Class Ia and Class III antiarrhythmics and some antipsychotics.

Medicinal products used in the treatment of gout (probenecid, sulfinpyrazone and allopurinol)

Dose adjustment of uricosuric medicinal products may be necessary as hydrochlorothiazide may raise the level of serum uric acid. Increase of dose of probenecid or sulfinpyrazone may be necessary.

 

Co-administration of thiazide diuretics, including hydrochlorothiazide, may increase the incidence of hypersensitivity reactions to allopurinol.

Methyldopa

There have been isolated reports of haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and methyldopa.

Non-depolarising skeletal muscle relaxants (e.g. tubocurarine)

Thiazides, including hydrochlorothiazide, potentiate the action of curare derivatives.

Other anti-hypertensive medicinal products

Thiazides potentiate the antihypertensive action of other antihypertensive drugs (e.g. guanethidine, methyldopa, beta- blockers, vasodilators, calcium channel blockers, ACE inhibitors, ARBs and Direct Renin Inhibitors [DRIs]).

Pressor amines (e.g. noradrenaline, adrenaline)

Hydrochlorothiazide may reduce the response to pressor amines such as noradrenaline. The clinical significance of this effect is uncertain and not sufficient to preclude their use.

Vitamin D and calcium salts

Administration of thiazide diuretics, including hydrochlorothiazide, with vitamin D or with calcium salts may potentiate the rise in serum calcium. Concomitant use of thiazide type diuretics may lead to hypercalcaemia in patients pre- disposed for hypercalcaemia (e.g. hyperparathyroidism, malignancy or vitamin-D-mediated conditions) by increasing tubular calcium reabsorption.

 

Dual blockade of the RAAS with ARBs, ACE inhibitors or aliskiren

 

Clinical trial data have shown that dual blockade of the RAAS through the combined use of ACE inhibitors, ARBs or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).


Pregnancy Category: D

 

Pregnancy

 

Amlodipine

 

The safety of amlodipine in human pregnancy has not been established. In animal studies, reproductive toxicity was observed at high doses (see section 5.3). Use in pregnancy is only recommended when there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.

 

 
 


Valsartan

 

 

Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and if appropriate, alternative therapy should be started.

 

Exposure to AIIRAs therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).

 

Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.

 

Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).

 

Hydrochlorothiazide

 

There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient.

 

Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide, its use during the second and third trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.

 

Amlodipine/valsartan/hydrochlorothiazide

 

There is no experience on the use of Arbavasc HCT in pregnant women. Based on the existing data with the components, the use of Arbavasc HCT is not recommended during first trimester and contra-indicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).

 

Breast-feeding

 

No information is available regarding the use of valsartan and/or amlodipine during breast-feeding. Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense diuresis can inhibit milk production. The use of Arbavasc HCT during breast-feeding is not recommended. If Arbavasc HCT is used during breast-feeding, doses should be kept as low as possible. Alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.

 

Fertility

 

There are no clinical studies on fertility with Arbavasc HCT.

 

Valsartan

 

Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200 mg/kg/day. This dose is 6 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).

 

Amlodipine

 

Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section 5.3).


Patients taking Arbavasc HCT and driving vehicles or using machines should take into account that
dizziness or weariness may occasionally occur.
Amlodipine can have mild or moderate influence on the ability to drive and use machines. If patients taking
Arbavasc HCT suffer from dizziness, headache, fatigue or nausea the ability to react may be impaired


 


1.1    The safety profile of Arbavasc HCT presented below is based on clinical studies performed with Arbavasc HCT and the known safety profile of the individual components amlodipine, valsartan and hydrochlorothiazide.

 

A. Summary of the safety profile

 

The safety of Arbavasc HCT has been evaluated at its maximum dose of 10 mg/320 mg/25 mg in one controlled short- term (8 weeks) clinical study with 2,271 patients, 582 of whom received valsartan in combination with amlodipine and hydrochlorothiazide. Adverse reactions were generally mild and transient in nature and only infrequently required discontinuation of therapy. In this active controlled clinical trial, the most common reasons for discontinuation of therapy with Arbavasc HCT were dizziness and hypotension (0.7%).

 

In the 8-week controlled clinical study, no significant new or unexpected adverse reactions were observed with triple therapy treatment compared to the known effects of the monotherapy or dual therapy components.

 

In the 8-week controlled clinical study, changes in laboratory parameters observed with the combination of Arbavasc HCT were minor and consistent with the pharmacological mechanism of action of the monotherapy agents. The presence of valsartan in the triple combination attenuated the hypokalaemic effect of hydrochlorothiazide.

 

B.  Tabulated list of adverse reactions

 

The following adverse reactions, listed by MedDRA System Organ Class and frequency, concern Arbavasc HCT (amlodipine/valsartan/HCT) and amlodipine, valsartan and HCT individually.

 

Very common: ≥1/10; common: ≥1/100 to <1/10; uncommon: ≥1/1,000 to <1/100; rare: ≥1/10,000 to <1/1,000; very rare: <1/10,000, not known (cannot be estimated from the available data).

 

MedDRA System Organ Class

Adverse reactions

Frequency

 

 

 

Arbavasc HCT

Amlodipine

Valsartan

HCT

 

Blood and lymphatic system disorders

Agranulocytosis, bone marrow failure

--

--

--

Very rare

Haemoglobin and haematocrit decreased

--

--

Not known

--

Haemolytic anaemia

--

--

--

Very rare

Leukopenia

--

Very rare

--

Very rare

Neutropenia

--

--

Not known

--

Thrombocytopenia, sometimes with purpura

--

Very rare

Not known

Rare

Aplastic anaemia

--

--

--

Not known

Immune system disorders

Hypersensitivity

--

Very rare

Not known

Very rare

Metabolism and nutrition disorders

Anorexia

Uncommon

--

--

--

Hypercalcaemia

Uncommon

--

--

Rare

Hyperglycaemia

--

Very rare

--

Rare

Hyperlipidaemia

Uncommon

--

--

--

Hyperuricaemia

Uncommon

--

--

Common

Hypochloraemic alkalosis

--

--

--

Very rare

Hypokalaemia

Common

--

--

Very common

Hypomagnesaemia

--

--

--

Common

Hyponatraemia

Uncommon

--

--

Common

Worsening of diabetic metabolic state

--

--

--

Rare

Psychiatric disorders

Depression

--

Uncommon

--

Rare

Insomnia/sleep disorders

Uncommon

Uncommon

--

Rare

Mood swings

--

Uncommon

--

 

Confusion

--

Rare

--

--

Nervous system disorders

Coordination abnormal

Uncommon

--

--

--

Dizziness

Common

Common

--

Rare

Dizziness postural, dizziness exertional

Uncommon

--

--

--

Dysgeusia

Uncommon

Uncommon

--

--

Extrapyramidal syndrome

--

Not known

--

--

Headache

Common

Common

--

Rare

Hypertonia

--

Very rare

--

--

Lethargy

Uncommon

--

--

--

Paraesthesia

Uncommon

Uncommon

--

Rare

 

 

Peripheral neuropathy, neuropathy

Uncommon

Very rare

--

--

Somnolence

Uncommon

Common

--

--

Syncope

Uncommon

Uncommon

--

--

Tremor

--

Uncommon

--

--

Hypoesthesia

--

Uncommon

--

--

Eye disorders

Acute angle-closure glaucoma

--

--

--

Not known

Visual disturbance

--

Uncommon

--

--

Visual impairment

Uncommon

Uncommon

--

Rare

Choroidal effusion

--

--

--

Not known

Ear and labyrinth disorders

Tinnitus

--

Uncommon

--

--

Vertigo

Uncommon

--

Uncommon

--

Cardiac disorders

Palpitations

--

Common

--

--

Tachycardia

Uncommon

--

--

--

Arrhythmias (including bradycardia, ventricular tachycardia, and atrial fibrillation)

--

Very rare

--

Rare

Myocardial infarction

--

Very rare

--

--

Vascular disorders

Flushing

--

Common

--

--

Hypotension

Common

Uncommon

--

--

Orthostatic hypotension

Uncommon

--

--

Common

Phlebitis, thrombophlebitis

Uncommon

--

--

--

Vasculitis

--

Very rare

Not known

--

Respiratory, thoracic and mediastinal disorders

Cough

Uncommon

Very rare

Uncommon

--

Dyspnoea

Uncommon

Uncommon

--

--

Respiratory distress, pulmonary oedema, pneumonitis

--

--

--

Very rare

Rhinitis

--

Uncommon

--

--

Throat irritation

Uncommon

--

--

--

Gastrointestinal disorders

Abdominal discomfort, abdominal pain upper

Uncommon

Common

Uncommon

Rare

Breath odour

Uncommon

--

--

--

Change of bowel habit

--

Uncommon

--

--

Constipation

--

--

--

Rare

Decreased appetite

--

--

--

Common

Diarrhoea

Uncommon

Uncommon

--

Rare

Dry mouth

Uncommon

Uncommon

--

--

 

 

Dyspepsia

Common

Uncommon

--

--

Gastritis

--

Very rare

--

--

Gingival hyperplasia

--

Very rare

--

--

Nausea

Uncommon

Common

--

Common

Pancreatitis

--

Very rare

--

Very rare

Vomiting

Uncommon

Uncommon

--

Common

Hepatobiliary disorders

Liver function test abnormal, including blood bilirubin increase

--

Very rare**

Not known

--

Hepatitis

--

Very rare

--

--

Intrahepatic cholestasis, jaundice

--

Very rare

--

Rare

Skin and subcutaneous tissue disorders

Alopecia

--

Uncommon

--

 

Angioedema

--

Very rare

Not known

--

Dermatitis bullous

--

--

Not known

--

Cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus

--

--

--

Very rare

Erythema multiforme

--

Very rare

--

Not known

Exanthema

--

Uncommon

--

--

Hyperhidrosis

Uncommon

Uncommon

--

--

Photosensitivity reaction*

--

Very rare

--

Rare

Pruritus

Uncommon

Uncommon

Not known

--

Purpura

--

Uncommon

--

Rare

Rash

--

Uncommon

Not known

Common

Skin discoloration

--

Uncommon

--

--

Urticaria and other forms of rash

--

Very rare

--

Common

Vasculitis necrotising and toxic epidermal necrolysis

--

--

--

Very rare

Exfoliative dermatitis

--

Very rare

--

--

Stevens-Johnson syndrome

--

Very rare

--

--

Quincke oedema

--

Very rare

--

--

Musculoskeletal and connective tissue disorders

Arthralgia

--

Uncommon

--

--

Back pain

Uncommon

Uncommon

--

--

Joint swelling

Uncommon

--

--

--

Muscle spasm

Uncommon

Uncommon

--

Not known

Muscular weakness

Uncommon

--

--

--

 

 

Myalgia

Uncommon

Uncommon

Not known

--

Pain in extremity

Uncommon

--

--

--

Ankle swelling

--

Common

--

--

Renal and urinary disorders

Blood creatinine increased

Uncommon

--

Not known

--

Micturition disorder

 

Uncommon

 

 

Nocturia

--

Uncommon

--

--

Pollakiuria

Common

Uncommon

 

 

Renal dysfunction

--

--

--

Not known

Acute renal failure

Uncommon

--

--

Not known

Renal failure and impairment

--

--

Not known

Rare

Reproductive system and breast disorders

Impotence

Uncommon

Uncommon

--

Common

Gynaecomastia

 

Uncommon

--

--

General disorders and administration site conditions

Abasia, gait disturbance

Uncommon

--

--

--

Asthenia

Uncommon

Uncommon

--

Not known

Discomfort, malaise

Uncommon

Uncommon

--

--

Fatigue

Common

Common

Uncommon

--

Non cardiac chest pain

Uncommon

Uncommon

--

--

Oedema

Common

Common

--

--

Pain

--

Uncommon

--

--

Pyrexia

--

--

--

Not known

Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Non-melanoma skin cancer (Basal cell carcinoma and Squamous cell carcinoma).

 

 

 

Not know

Investigations

Lipids increased

 

--

 

Very common

Blood urea nitrogen increased

Uncommon

--

--

--

Blood uric acid increased

Uncommon

--

--

 

Glycosuria

 

 

 

Rare

Blood potassium decreased

Uncommon

--

--

--

Blood potassium increased

--

--

Not known

--

Weight increase

Uncommon

Uncommon

--

--

Weight decrease

--

Uncommon

--

--

 

 

* See section 4.4 Photosensitivity

 

** Mostly consistent with cholestasis

 

C.  Description of selected Side effects

 

Cases of choroidal effusion with visual field defect have been reported after the use of thiazide and thiazide-like diuretics. If cases are to be reported for these substances in the future, the appropriate procedure should be used to update the product information accordingly.

 

Non-melanoma skin cancer: Based on available data from epidemiological studies, cumulative dose-dependent association between HCTZ and NMSC has been observed (see also sections 4.4 and 5.1).

 

D.  Special population:

 

Renal impairment

 

Due to the hydrochlorothiazide component, Arbavasc HCT is contraindicated for use in patients with anuria (see section 4.3) and in patients with severe renal impairment (glomerular filtration rate (GFR) <30 ml/min/1.73 m2) (see sections 4.3, 4.4 and 5.2).

 

No adjustment of the initial dose is required for patients with mild to moderate renal impairment (see sections 4.4 and 5.2).

 

Hepatic impairment

 

Due to the valsartan component, Arbavasc HCT is contraindicated in patients with severe hepatic impairment (see section 4.3). In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan and therefore Arbavasc HCT is not suitable in this group of patients (see sections 4.3, 4.4 and 5.2). Amlodipine dose recommendations have not been established in patients with mild to moderate hepatic impairment. When switching eligible hypertensive patients (see section 4.1) with hepatic impairment to Arbavasc HCT, the lowest available dose of the amlodipine component should be used.

 

Heart failure and coronary artery disease

 

There is limited experience with the use of Arbavasc HCT, particulary at the maximum dose, in patients with heart failure and coronary artery disease. Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Arbavasc HCT, 10 mg/320 mg/25 mg.

 

Elderly (age 65 years or over)

 

Caution, including more frequent monitoring of blood pressure, is recommended in elderly patients, particularly at the maximum dose of Arbavasc HCT, 10 mg/320 mg/25 mg, since available data in this patient population are limited.

When switching eligible elderly hypertensive patients (see section 4.1) to Arbavasc HCT, the lowest available dose of the amlodipine component should be used.

 

E.  Paediatric population

 

There is no relevant use of Arbavasc HCT in the paediatric population (patients below age 18 years) for the indication of essential hypertension.

 

 

To report any side effect(s):

·         Saudi Arabia

Text Box: The National Pharmacovigilance and Drug Safety Centre (NPC) o Fax: +966-11-205-7662
o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.
o	Toll free phone: 8002490000
o	E-mail: npc.drug@sfda.gov.sa
o	Website: www.sfda.gov.sa/npc

 

·         Other GCC States:

Text Box: Please contact the relevant competent authority.


Symptoms
There is no experience of overdose with Arbavasc HCT. The major symptom of overdose with
valsartan is possibly pronounced hypotension with dizziness. Overdose with amlodipine may result
in excessive peripheral vasodilation and, possibly, reflex tachycardia. Marked and potentially
prolonged systemic hypotension, including shock with fatal outcome, have been reported with
amlodipine.
Treatment
Amlodipine/Valsartan/Hydrochlorothiazide
Clinically significant hypotension due to Arbavasc HCT overdose calls for active cardiovascular
support, including frequent monitoring of cardiac and respiratory function, elevation of extremities,
and attention to circulating fluid volume and urine output. A vasoconstrictor may be helpful in
restoring vascular tone and blood pressure, provided that there is no contraindication to its use.
Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel
blockade.
Amlodipine
If ingestion is recent, induction of vomiting or gastric lavage may be considered. Administration of
activated charcoal to healthy volunteers immediately or up to two hours after ingestion of
amlodipine has been shown to significantly decrease amlodipine absorption.
Amlodipine is unlikely to be removed by haemodialysis.
Valsartan
Valsartan is unlikely to be removed by haemodialysis.
Hydrochlorothiazide
Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia,
hypochloraemia) and hypovolaemia resulting from excessive diuresis. The most common signs and
symptoms of overdose are nausea and somnolence. Hypokalaemia may result in muscle spasms and
or accentuate arrhythmia associated with the concomitant use of digitalis glycosides or certain anti-
arrhythmic medicinal products.
The degree to which hydrochlorothiazide is removed by haemodialysis has not been established


 


Pharmacotherapeutic group: Agents acting on the renin-angiotensin system, angiotensin II
antagonists, other combinations, ATC code: C09DX01.
Mechanism of action
Arbavasc HCT combines three antihypertensive compounds with complementary mechanisms to
control blood pressure in patients with essential hypertension: amlodipine belongs to the calcium
antagonist class and valsartan to the angiotensin II antagonist class of medicines and
hydrochlorothiazide belongs to the thiazide diuretics class of medicines. The combination of these
substances has an additive antihypertensive effect.
Amlodipine/Valsartan/Hydrochlorothiazide
Clinical efficacy and safety
Arbavasc HCT was studied in a double-blind, active controlled study in hypertensive patients. A total
of 2,271 patients with moderate to severe hypertension (mean baseline systolic/diastolic blood
pressure was 170/107 mmHg) received treatments of amlodipine/valsartan/hydrochlorothiazide 10
mg/320 mg/25 mg, valsartan/hydrochlorothiazide 320 mg/25 mg, amlodipine/valsartan 10 mg/320
mg, or hydrochlorothiazide/amlodipine 25 mg/10 mg. At study initiation patients were assigned lower
doses of their treatment combination and were titrated to their full treatment dose by week 2.
At week 8, the mean reductions in systolic/diastolic blood pressure were 39.7/24.7 mmHg with
Arbavasc HCT, 32.0/19.7 mmHg with valsartan/hydrochlorothiazide, 33.5/21.5 mmHg with
amlodipine/valsartan, and 31.5/19.5 mmHg with amlodipine/hydrochlorothiazide. The triple
combination therapy was statistically superior to each of the three dual combination treatments in
reduction of diastolic and systolic blood pressures. The reductions in systolic/diastolic blood pressure
with Arbavasc HCT were 7.6/5.0 mmHg greater than with valsartan/hydrochlorothiazide, 6.2/3.3
mmHg greater than with amlodipine/valsartan, and 8.2/5.3 mmHg greater than with
amlodipine/hydrochlorothiazide. The full blood pressure lowering effect was achieved 2 weeks after
being on their maximal dose of Arbavasc HCT. Statistically greater proportions of patients achieved
blood pressure control (<140/90 mmHg) with Arbavasc HCT (71%) compared to each of the three
dual combination therapies (45-54%) (p<0.0001).
In a subgroup of 283 patients focusing on ambulatory blood pressure monitoring, clinically and
statistically superior reductions in 24-hour systolic and diastolic blood pressures were observed with
the triple combination compared to valsartan/hydrochlorothiazide, valsartan/amlodipine, and
hydrochlorothiazide/amlodipine.
Amlodipine
Mechanism of action
The amlodipine component of Arbavasc HCT inhibits the transmembrane entry of calcium ions into
cardiac and vascular smooth muscle. The mechanism of the antihypertensive action of amlodipine is
due to a direct relaxant effect on vascular smooth muscle, causing reductions in peripheral vascular
resistance and in blood pressure.
Pharmacodynamic effects
Experimental data suggest that amlodipine binds to both dihydropyridine and non-dihydropyridine
binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent
upon the movement of extracellular calcium ions into these cells through specific ion channels.
Following administration of therapeutic doses to patients with hypertension, amlodipine produces
vasodilation, resulting in a reduction of supine and standing blood pressures. These decreases in
blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine
levels with chronic dosing.
Plasma concentrations correlate with effect in both young and elderly patients.
In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a
decrease in renal vascular resistance and increases in glomerular filtration rate and effective renal
plasma flow, without change in filtration fraction or proteinuria.
As with other calcium channel blockers, haemodynamic measurements of cardiac function at rest and
during exercise (or pacing) in patients with normal ventricular function treated with amlodipine have
generally demonstrated a small increase in cardiac index without significant influence on dP/dt or on
left ventricular end diastolic pressure or volume. In haemodynamic studies, amlodipine has not been
associated with a negative inotropic effect when administered in the therapeutic dose range to intact
animals and humans, even when co-administered with beta blockers to humans.
Amlodipine does not change sinoatrial nodal function or atrioventricular conduction in intact animals
or humans. In clinical studies in which amlodipine was administered in combination with beta
blockers to patients with either hypertension or angina, no adverse effects on electrocardiographic
parameters were observed.
Amlodipine has been studied in patients with chronic stable angina, vasospastic angina and
angiographically documented coronary artery disease.
Clinical efficacy and safety
Use in patients with hypertension
A randomised double-blind morbidity-mortality study called the Antihypertensive and Lipid
Lowering treatment to prevent Heart Attack Trial (ALLHAT) was performed to compare newer
therapies: amlodipine 2.5-10 mg/day (calcium channel blocker) or lisinopril 10-40 mg/day (ACE
inhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/day in mild
to moderate hypertension.
A total of 33,357 hypertensive patients aged 55 or older were randomised and followed for a mean of
4.9 years. The patients had at least one additional coronary heart disease risk factor, including:
previous myocardial infarction or stroke (>6 months prior to enrollment) or documentation of other
atherosclerotic cardiovascular disease (overall 51.5%), type 2 diabetes (36.1%), high density
lipoprotein - cholesterol <35 mg/dl or <0.906 mmol/l (11.6%), left ventricular hypertrophy diagnosed
by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).
The primary endpoint was a composite of fatal coronary heart disease or non-fatal myocardial
infarction. There was no significant difference in the primary endpoint between amlodipine-based
therapy and chlorthalidone-based therapy: risk ratio (RR) 0.98 95% CI (0.90-1.07) p=0.65. Among
secondary endpoints, the incidence of heart failure (component of a composite combined
cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the
chlorthalidone group (10.2% versus 7.7%, RR 1.38, 95% CI [1.25-1.52] p<0.001). However, there
was no significant difference in all-cause mortality between amlodipine-based therapy and
chlorthalidone-based therapy RR 0.96 95% CI [0.89-1.02] p=0.20.
Valsartan
Mechanism of action
Valsartan is an orally active, potent and specific angiotensin II receptor antagonist. It acts selectively
on the receptor subtype AT1, which is responsible for the known actions of angiotensin II.
Clinical efficacy and safety
Administration of valsartan to patients with hypertension results in a drop in blood pressure without
affecting pulse rate.
In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs
within 2 hours, and the peak drop in blood pressure is achieved within 4-6 hours. The
antihypertensive effect persists over 24 hours after administration. During repeated administration,
the maximum reduction in blood pressure with any dose is generally attained within 2-4 weeks.
Hydrochlorothiazide
Mechanism of action
The site of action of thiazide diuretics is primarily in the renal distal convoluted tubule. It has been
shown that there is a high-affinity receptor in the renal cortex as the primary binding site for the
thiazide diuretic action and inhibition of NaCl transport in the distal convoluted tubule. The mode of
action of thiazides is through inhibition of the Na+Cl- symporter perhaps by competing for the Cl- site,
thereby affecting electrolyte reabsorption mechanisms: directly increasing sodium and chloride
excretion to an approximately equal extent, and indirectly, by this diuretic action, reducing plasma
volume, with consequent increases in plasma renin activity, aldosterone secretion and urinary
potassium loss, and a decrease in serum potassium.
Paediatric population
The European Medicines Agency has waived the obligation to submit the results of studies with
Arbavasc HCT in all subsets of the paediatric population in essential hypertension (see section 4.2 for
information on paediatric use).
Other: dual blockade of the renin-angiotensin-aldosterone system (RAAS)
Two large randomised, controlled trials (ONTARGET [ONgoing Telmisartan Alone and in
combination with Ramipril Global Endpoint Trial] and VA NEPHRON-D [The Veterans Affairs
Nephropathy in Diabetes]) have examined the use of the combination of an ACE inhibitor with an
ARB.
ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular
disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON
D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.
These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes
and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as
compared to monotherapy was observed. Given their similar pharmacodynamic properties, these
results are also relevant for other ACE inhibitors and ARBs.
ACE inhibitors and ARBs should therefore not be used concomitantly in patients with diabetic
nephropathy (see section 4.4).
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints)
was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE inhibitor
or an ARB in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular
disease, or both. The study was terminated early because of an increased risk of adverse outcomes.
Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in
the placebo group and adverse events and serious adverse events of interest (hyperkalaemia,
hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the
placebo group


 


Linearity
Amlodipine, valsartan and hydrochlorothiazide exhibit linear pharmacokinetics.
Amlodipine/valsartan/hydrochlorothiazide
Following oral administration of Arbavasc HCT in normal healthy adults, peak plasma
concentrations of amlodipine, valsartan and hydrochlorothiazide are reached in 6-8 hours, 3 hours,
and 2 hours, respectively. The rate and extent of absorption of amlodipine, valsartan and
hydrochlorothiazide from Arbavasc HCT are the same as when administered as individual dosage
forms.
Amlodipine
Absorption
After oral administration of therapeutic doses of amlodipine alone, peak plasma concentrations of
amlodipine are reached in 6-12 hours. Absolute bioavailability has been calculated as between 64%
and 80%. Amlodipine bioavailability is unaffected by food ingestion.
Distribution
Volume of distribution is approximately 21 l/kg. In vitro studies with amlodipine have shown that
approximately 97.5% of circulating drug is bound to plasma proteins.
Biotransformation
Amlodipine is extensively (approximately 90%) metabolised in the liver to inactive metabolites.
Elimination
Amlodipine elimination from plasma is biphasic, with a terminal elimination half-life of
approximately 30 to 50 hours. Steady-state plasma levels are reached after continuous administration
for 7-8 days. Ten per cent of original amlodipine and 60% of amlodipine metabolites are excreted in
urine.
Valsartan
Absorption
Following oral administration of valsartan alone, peak plasma concentrations of valsartan are
reached in 2-4 hours. Mean absolute bioavailability is 23%. Food decreases exposure (as measured
by AUC) to valsartan by about 40% and peak plasma concentration (Cmax) by about 50%, although
from about 8 h post dosing plasma valsartan concentrations are similar for the fed and fasted groups.
This reduction in AUC is not, however, accompanied by a clinically significant reduction in the
therapeutic effect, and valsartan can therefore be given either with or without food.
Distribution


 

The steady-state volume of distribution of valsartan after intravenous administration is about 17
litres, indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound
to serum proteins (94-97%), mainly serum albumin.
Biotransformation
Valsartan is not transformed to a high extent as only about 20% of dose is recovered as metabolites.
A hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the
valsartan AUC). This metabolite is pharmacologically inactive.
Elimination
Valsartan shows multiexponential decay kinetics (t½α <1 h and t½ß about 9 h). Valsartan is primarily
eliminated in faeces (about 83% of dose) and urine (about 13% of dose), mainly as unchanged drug.
Following intravenous administration, plasma clearance of valsartan is about 2 l/h and its renal
clearance is 0.62 l/h (about 30% of total clearance). The half-life of valsartan is 6 hours.
Hydrochlorothiazide
Absorption
The absorption of hydrochlorothiazide, after an oral dose, is rapid (Tmax about 2 hours). The increase
in mean AUC is linear and dose proportional in the therapeutic range.
The effect of food on hydrochlorothiazide absorption, if any, has little clinical significance. Absolute
bioavailability of hydrochlorothiazide is 70% after oral administration.
Distribution
The apparent volume of distribution is 4-8 l/kg. Circulating hydrochlorothiazide is bound to serum
proteins (40-70%), mainly serum albumin. Hydrochlorothiazide also accumulates in erythrocytes at
approximately 3 times the level in plasma.
Biotransformation
Hydrochlorothiazide is eliminated predominantly as unchanged compound.
Elimination
Hydrochlorothiazide is eliminated from plasma with a half-life averaging 6 to 15 hours in the
terminal elimination phase. There is no change in the kinetics of hydrochlorothiazide on repeated
dosing, and accumulation is minimal when dosed once daily. More than 95% of the absorbed dose is
being excreted as unchanged compound in the urine. The renal clearance is composed of passive
filtration and active secretion into the renal tubule.
Special populations
Paediatric patients (age below 18 years)
No pharmacokinetic data are available in the paediatric population.
Elderly (age 65 years or over)
Time to peak plasma amlodipine concentrations is similar in young and elderly patients. In elderly
patients, amlodipine clearance tends to decline, causing increases in the area under the curve (AUC)
and elimination half-life. Mean systemic AUC of valsartan is higher by 70% in the elderly than in
the young, therefore caution is required when increasing the dosage.
Systemic exposure to valsartan is slightly elevated in the elderly as compared to the young, but this
has not been shown to have any clinical significance.
Limited data suggest that the systemic clearance of hydrochlorothiazide is reduced in both healthy
and hypertensive elderly subjects compared to young healthy volunteers.
Since the three components are equally well tolerated in younger and elderly patients, normal dose
regimens are recommended (see section 4.2).
Renal impairment
The pharmacokinetics of amlodipine are not significantly influenced by renal impairment. As
expected for a compound where renal clearance accounts for only 30% of total plasma clearance, no
correlation was seen between renal function and systemic exposure to valsartan.
Patients with mild to moderate renal impairment may therefore receive the usual initial dose (see
sections 4.2 and 4.4).
In the presence of renal impairment, mean peak plasma levels and AUC values of
hydrochlorothiazide are increased and the urinary excretion rate is reduced. In patients with mild to
moderate renal impairment, a 3-fold increase in hydrochlorothiazide AUC has been observed. In
patients with severe renal impairment an 8-fold increase in AUC has been observed. Arbavasc HCT
is contraindicated in patients with severe renal impairment, anuria or undergoing dialysis (see
section 4.3).
Hepatic impairment
Very limited clinical data are available regarding amlodipine administration in patients with hepatic
impairment. Patients with hepatic impairment have decreased clearance of amlodipine with resulting
increase of approximately 40–60% in AUC. On average, in patients with mild to moderate chronic
liver disease, exposure (measured by AUC values) to valsartan is twice that found in healthy
volunteers (matched by age, sex and weight). Due to the valsartan component, Arbavasc HCT is
contraindicated in patients with hepatic impairment (see sections 4.2 and 4.3)


 


Amlodipine/Valsartan/Hydrochlorothiazide
In a variety of preclinical safety studies conducted in several animal species with amlodipine,
valsartan, hydrochlorothiazide, valsartan/hydrochlorothiazide, amlodipine/valsartan and
amlodipine/valsartan/hydrochlorothiazide (Arbavasc HCT), there was no evidence of systemic or
target organ toxicity that would adversely affect the development of Arbavasc HCT for clinical use in
humans.
Preclinical safety studies of up to 13 weeks in duration were conducted with amlodipine/
valsartan/hydrochlorothiazide in rats. The combination resulted in expected reduction of red blood
cell mass (erythrocytes, haemoglobin, haematocrit, and reticulocytes), increase in serum urea,
increase in serum creatinine, increase in serum potassium, juxtaglomerular (JG) hyperplasia in the
kidney and focal erosions in the glandular stomach in rats. All these changes were reversible after a 4-
week recovery period and were considered to be exaggerated pharmacological effects.
The amlodipine/valsartan/hydrochlorothiazide combination was not tested for genotoxicity or
carcinogenicity as there was no evidence of any interaction between these substances, which have
been on the market for a long time. However, amlodipine, valsartan and hydrochlorothiazide have
been tested individually for genotoxicity and carcinogenicity with negative results.
Amlodipine
Reproductive toxicology
Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of
labour and decreased pup survival at dosages approximately 50 times greater than the maximum
recommended dosage for humans based on mg/kg.
Impairment of fertility
There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14
days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose
of 10 mg on a mg/m2 basis). In another rat study in which male rats were treated with amlodipine
besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma
follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in
the number of mature spermatids and Sertoli cells.
Carcinogenesis, mutagenesis
Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to
provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity.
The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose


 

of 10 mg on a mg/m2 basis) was close to the maximum tolerated dose for mice but not for rats.
Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.
* Based on patient weight of 50 kg
Valsartan
Non-clinical data reveal no special hazard for humans based on conventional studies of safety
pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction
and development.
In rats, maternally toxic doses (600 mg/kg/day) during the last days of gestation and lactation led to
lower survival, lower weight gain and delayed development (pinna detachment and ear-canal
opening) in the offspring (see section 4.6). These doses in rats (600 mg/kg/day) are approximately 18
times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of
320 mg/day and a 60-kg patient).
In non-clinical safety studies, high doses of valsartan (200 to 600 mg/kg body weight) caused in rats a
reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit) and evidence of
changes in renal haemodynamics (slightly raised blood urea nitrogen, and renal tubular hyperplasia
and basophilia in males). These doses in rats (200 and 600 mg/kg/day) are approximately 6 and 18
times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of
320 mg/day and a 60-kg patient).
In marmosets at comparable doses, the changes were similar though more severe, particularly in the
kidney where the changes developed to a nephropathy including raised blood urea nitrogen and
creatinine.
Hypertrophy of the renal juxtaglomerular cells was also seen in both species. All changes were
considered to be caused by the pharmacological action of valsartan which produces prolonged
hypotension, particularly in marmosets. For therapeutic doses of valsartan in humans, the hypertrophy
of the renal juxtaglomerular cells does not seem to have any relevance


 


• Microcrystalline cellulose
• Crospovidone
• Colloidal Silicon Dioxide
• Magnesium Stearate
• Opadry


 


Not applicable


 


4 Years

Keep out of reach and sight of children.
Store below 30°C.
Do not use Arbavasc HCT after the expiry date which is stated on the carton and blister after
EXP. The expiry date refers to the last day of that month.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how
to throw away medicines you no longer use. These measures will help protect the environment


 


Arbavasc HCT 160/5/12.5 mg is White Oval shaped biconvex core tablet embossed with SJ523
from one side packed in Alu/Alu blister
Arbavasc HCT 160/5/25 mg is Yellow Oval shaped biconvex core tablet embossed with SJ527
from one side packed in Alu/Alu blister
Arbavasc HCT 160/10/12.5 mg is Pale yellow oval shaped biconvex film coated tablet embossed
with SJ525 in one side packed in Alu/Alu blister
Arbavasc HCT 160/10/25 mg is Brownish yellow oval shaped biconvex film coated tablet
embossed with SJ531 in one side packed in Alu/Alu blister


 


No special requirements


 


SAJA Pharmaceuticals

October 2020
}

صورة المنتج على الرف

الصورة الاساسية